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Ischemic injury occurs when the flow of blood is reduced or blocked to an area of 
the body and can cause significant tissue damage by generation of reactive oxygen 
species (ROS), activation of apoptotic pathways and through induction of the 
inflammatory response. Restoration of blood flow and reperfusion of the blocked site, 
while essential, can generate a second injury that itself needs to be controlled. Together 
the two injuries are termed ischemia/reperfusion (I/R) injury. This type of injury is 
frequently encountered in medicine and is a major medical problem. Therapeutic 
strategies to combat I/R injury include the introduction of compounds that can scavenge 
ROS or can induce metabolic pathways with the effect of inhibiting apoptosis. Caffeic 
Acid Phenethyl Ester (CAPE), a polyphenolic compound found in propolis, has been 
shown to protect a variety of cells types against ROS in vitro and has also been shown to 
induce a variety of genes including hemeoxygenase 1 (HMOX-1) , an enzyme that has 
been implicated in a cytoprotective pathway. Despite showing significant cytoprotection 
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of cells against oxidant stress in vitro, CAPE is readily hydrolyzed in plasma and is also 
quickly removed from circulation. This result may explain the limited cytoprotective 
effects of CAPE in vivo.  We have synthesized a series of CAPE amide derivatives, 
including Caffeic Acid Phenethyl Amide (CAPA), with the aim of improving CAPE’s 
stability properties while maintaining the cytoprotective effects of the parent compound. 
We found that CAPA, in addition to 2 other amide derivatives, were able to protect 
human umbilical vein endothelial cells (HUVEC) against ROS to a similar degree as 
CAPE. In addition, we have observed significant improvement in plasma stability of 
CAPA over CAPE at multiple temperatures. The elimination half-life of CAPA from the 
systemic circulation was also seen to be significantly improved over CAPE following 
intravenous administration to male Sprague-Dawley rats. The longer residence time of 
CAPA over CAPE in circulation may potentially result in greater cytoprotection in vivo. 
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Statement of Objectives and Significance of Research 
Ischemia reperfusion (I/R) injury describes a dysfunctional physiological state 
that results from tissue hypoxia followed by reoxygenation. I/R injury can manifest 
following a variety of routine surgical procedures and is a broad underlying mechanism 
of cellular damage in a number of conditions including cardiovascular disease. Clinical 
implications of I/R injury are diverse and can include reperfusion arrhythmia, impairment 
of brain function, or systemic inflammatory response syndrome that may progress to  
multiple organ dysfunction syndrome. A large body of experimental data supports the 
claim that reactive oxygen species (ROS) produced during reperfusion play a significant 
role in the development of I/R injury. Radical scavengers and antioxidants have been 
administered in attempts to ameliorate the damage caused by I/R injury with varying 
degrees of success in animal models. One such compound is Caffeic Acid Phenethyl 
Ester (CAPE), which has been found to reduce the effects of I/R when administered pre 
injury in rats and rabbits. CAPE is also cited to have numerous other beneficial effects 
including antioxidant, anti-viral, anti-inflammatory and immuno-modulatory activities. It 
was also shown however that CAPE is quickly hydrolyzed in vitro and removed rapidly 
from the circulation in vivo. If the half-life of CAPE in the circulation were to be 
significantly increased without compromising the desirable activities of the compound, 
the beneficial effects of CAPE might be extended and/or improved. This dissertation is a 
summary of research activities aimed at structurally altering CAPE such that in vitro 
stability and in vivo half-life would be significantly increased while maintaining the 
cytoprotective properties of CAPE. Listed below are the specific objectives followed 
during the course of this research project. 
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1) Synthesize an amide derivative of CAPE, Caffeic Acid Phenethyl Amide (CAPA), 
along with five additional fluorinated amide analogues. 
 
2) Develop a cytoprotection assay against oxidative stress using human umbilical vein 
endothelial cells (HUVEC) to compare the protective activities of CAPE with the newly 
synthesized analogues. 
 
3) Attempt to establish structure activity relationships between the CAPA derivatives and 
cytoprotective activity against oxidative stress 
 
4) Investigate the chemical stability of CAPE and CAPA in rat plasma to determine 
whether amide derivatization increased in vitro stability. 
 
5) Develop a liquid chromatography mass spectrometry (LCMS) method for the 
quantitative determination of CAPE and CAPA in blood plasma. 
 
6) Characterize the pharmacokinetic profile of CAPE and CAPA in male Sprague-








Chapter 1 – Background and Literature Review 
 
1.1 – MECHANISM OF ISCHEMIA / REPERFUSION INJURY 
 
 
Ischemia is characterized by hypoperfusion of vascular beds resulting in a shortage of 
oxygen and other nutrients being supplied to the tissues as well as the accumulation of 
waste products and is an underlying pathological event in a variety of clinical conditions 
including cardiovascular disease, the global leading cause of death [1-2]. As a function of 
age, the endothelial lining of the vasculature is less well able to provide a 
nonthrombogenic surface, leading to the formation of blood clots that block vessels in the 
heart or brain leading to myocardial infarction or stroke. This oxygen shortage 
additionally occurs when there is a reduction of blood flow to a tissue or an organ during 
procedures such as organ transplantation and cardiovascular and orthopedic surgeries [3]. 
Other events that can result in arterial blockage and subsequent ischemia include 
traumatic injury and tourniquet application. Interruption of blood flow resulting from 
these conditions can lead to deficiency of nutrients and oxygen, as well as reduced ability 
to remove waste products from the affected area. Inability to supply sufficient oxygen to 
meet metabolic demands can result in cell death and irreversible tissue damage if 
prolonged. Hypoxia impairs the process of oxidative phosphorylation in the cells of 
effected tissues leading to a marked decrease in the production of ATP and the 
interruption of multiple cellular processes [3]. Other consequences of reduced ATP in the 
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cell include increased glycolysis, decreased pH, clumping of nuclear chromatin, reduced 
function of the sodium potassium pump, detachment of ribosomes and lipid deposition 
[4]. Ischemia can also result in loss of calcium homeostasis in the cell, causing increased 
calcium levels and activation of enzymes such as phospholipases, proteases and 
endonucleases [3, 5]. The increased activity of these enzymes can work to disrupt 
membranes and proteins, and possibly cause nuclear chromatin damage [6-7]. In addition, 
the loss of calcium ion homeostasis can lead to mitochondrial membrane permeability 
and the loss of function of the electron transport chain. If the mitochondrion is severely 
compromised, cytochrome c may be released leading to the induction of apoptosis [8]. 
Prolonged interruptions to these cellular mechanisms can cause permanent tissue or organ 
injury, making the re-introduction of oxygen vital for restoring function. This 
reperfusion, however, initiates a complex cascade of events leading to inflammatory and 
oxidative damage both locally and systemically [9-10]. This phenomenon is known as 
ischemia / reperfusion (I/R) injury. 
 The concept of reperfusion injury was first introduced by Hearse in 1977 [11-12]. 
It was thought previously that the increase in apoptotic and necrotic cells upon oxygen re-
introduction was due to irreversible injury sustained to those cells prior to reperfusion. 
More recent experimental evidence however suggests that these cells damaged during 
reperfusion were indeed viable before re-oxygenation [13]. The reperfusion of a 
previously ischemic organ restores the possibility of aerobic metabolism and is essential 
for recovery, but will also result in an inflammatory response that can extend tissue 
damage beyond the original area of ischemia [14].  This inflammatory state can 
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potentially persist for several days and may induce apoptosis on vascular structures [15-
17]. Studies have shown that I/R injury can trigger the activation of the complement 
system in different organs [3, 18]. The inflammatory response induced by complement 
activation, namely C5a and C5b, can include neutrophil mobilization, NFκB induction 
and release of inflammatory mediators such as TNF-α, IL-1 and IL-6 [19-22]. The release 
of reactive oxygen species (ROS) as a result of this inflammatory response is thought to 
contribute significantly to the damage caused in the event of an I/R injury [11, 23]. 
A large body of experimental evidence implicates the activity of ROS in the 
exacerbation of tissue injury following reperfusion [11, 24-27]. This group of unstable 
and highly reactive oxygen derived compounds includes hydrogen peroxide (H2O2), 
superoxide anion (O2
-
) and hydroxyl radical (OH●). These ROS accumulate in substantial 
amounts under I/R conditions and can significantly damage tissues if untreated [11, 24-
26, 28]. Under normal conditions, these oxygen free radicals are produced in small 
amounts. The majority of oxygen (95%) is safely reduced to H2O in the mitochondria 
under normal conditions, whereas the remaining 5% undergoes univalent reduction to 
superoxide (O2
-
). The cell can normally control the small amount of superoxide generated 
through the activity of the antioxidant enzymes superoxide dismutase and catalase, which 
convert superoxide to hydrogen peroxide and subsequently to water [28-31]. Under I/R 
conditions however, there is excessive production of ROS that the cell cannot sufficiently 
inactivate. During ischemia, there are inadequate amounts of oxygen available, which 
leads to ATP deficiency as well as the loss of sodium, calcium, and potassium ion 
regulation within the cell [5]. Without oxygen to serve as the final electron acceptor in 
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the electron transport chain (ETC), mitochondria are unable to produce ATP and the 
oxidative phosphorylation pathway begins to form increased amounts of ROS 
intermediates. In addition, high amounts of calcium caused by the loss of ionic 
homeostasis may induce the mitochondrial permeability transition [32-33]. This transition 
causes the formation of permeable pores from the inner membrane to the outer membrane 
of the mitochondria and allows the efflux of ROS and calcium, propagating and 
exacerbating the oxidative stress. Another consequence of mitochondrial permeability is 
the movement of cytochrome c out of the mitochondrial inner membrane into the cytosol. 
Cytochrome c is a vital component of the ETC, and its removal may result in the further 
production of ROS intermediates due to a disturbed oxidative phosphorylation pathway 
[34-35]. When cytochrome c is present in the cytosol, the caspase pathway becomes 
activated and apoptosis is induced [36-38]. Cytochrome c movement may also be induced 
by the translocation of the bax protein from the cytosol to the outer mitochondrial 
membrane. Bax is a pro-apoptotic member of the bcl2 protein family, and promotes 
mitochondrial membrane permeability as well as cytochrome c movement when 
translocated [34]. This induction of apoptosis is an additional mechanism through which 
I/R injury manifests. 
Ischemic conditions and increased intracellular calcium levels promote the 
conversion of xanthine dehydrogenase to xanthine oxidase, an enzyme capable of 
generating ROS [5]. Evidence suggests that the activity of xanthine oxidase (XO) is 
another significant source of ROS production within the cell. Depletion of ATP by 
ischemia results in the formation of hypoxanthine. Xanthine oxidase then uses O2 as a 
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substrate to convert hypoxanthine to xanthine upon re-introduction of oxygen, generating 
the ROS superoxide anion in the process [39-40]. The proposed mechanism for this 































 These radicals generate an oxidative stress on the cell that can result in a number 
of consequences, such as lipid peroxidation and modification of a number of cellular 
proteins [6, 43, 45-47]. These changes can cause cellular defects such as interruption of 
the Ca
2+




 pump ATPase [48]. If the activity of ROS is 
allowed to proceed unchecked in the cell, irreversible damage may be caused to cellular 
structures, leading to potential apoptosis as described earlier, or necrosis. On a larger 
scale, this ROS induced oxidative stress can manifest into a variety of clinical conditions. 
It has been shown that ROS induced cytotoxicity in the myocardium can contribute to 
myocardial stunning [22, 49]. I/R injury resulting from head trauma or stroke can lead to 
disruption of the blood brain barrier, allowing for the infiltration of leukocytes. The ROS 
generated from these leukocytes can irreversibly damage potentially salvageable cells, 
which may result in worsened sensory or motor functions [50]. I/R injuries sustained in 
skeletal muscle are met with local ROS generation, leading to the sequestration of 
polymorphnuclear leukocytes within the skeletal muscle. These leukocytes further secrete 
ROS into the surrounding area, initiating a type of positive feedback loop of ROS release. 
The cytotoxicity caused by this burst in ROS can result in endothelial dysfunction and 







1.2 – ROLE OF ANTIOXIDANTS IN I/R INJURY TREATMENT 
 
The onset of ischemia will always result in irreversible damage to a group of cells 
in the affected area. Another group of cells will be potentially salvageable upon 
successful reperfusion of the tissue. Treatment of I/R injury revolves around maximizing 
the chance of recovery for this group of potentially salvageable cells. A worst case 
scenario arises when 100% of the salvageable cells experiences cell death. The ideal 
situation would be 100% recovery of the cells in the salvageable group. Treatment 
strategies for I/R injury vary in effectiveness and fall between the two extremes.  
The role of ROS in the pathology of I/R injury is significant and has prompted a 
number of studies investigating the use of radical scavengers as potential therapeutic 
options. These antioxidants and radical scavengers react with the ROS generated by an 
I/R episode and prevent their interaction with biological macromolecules. Melatonin, a 
naturally occurring antioxidant and radical scavenger, has been shown to attenuate 
cardiac [53] and renal [54] I/R injury in rats. When pre-treated with ascorbic acid, the 
extent of I/R damage in the kidneys of male rats was less severe [55]. N-acetylcysteine 
(NAC), an antioxidant thiol used for treatment of paracetamol poisoning, can also 
function as a radical scavenger and works to increase the amount of cellular glutathione, 
an endogenous anti-oxidant compound. NAC has been shown to protect against hepatic 
I/R injury in rats [56]. When administered to knee surgery patients, it was found that 
NAC and propofol both reduce the extent of I/R injury [57]. There has been recent 
interest in the use of plant derived compounds to attenuate I/R tissue damage. Many of 
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these metabolite compounds contain antioxidant phenolic groups and have been shown to 
reduce the effects of I/R injury in a variety of applications. The flavonoids rutin [58] and 
pycnogenol [59] have been reported to protect against renal I/R damage in rats. In 
addition, quercetin showed improved tissue conditions over control following cerebral 
[60], renal [61], and cardiac [62] I/R episodes. Resveratrol [63] and curcumin [64] have 
also been shown to protect against myocardial I/R injury in rats. 
The cytoprotection against I/R injury provided by these compounds is attributed 
to direct antioxidant and radical scavenging activity, though experimental data have 
shown that the induction of antioxidant activating genes as well as signal pathway 
modulation may play a role as well. A number of mitogen activated protein kinases 
(MAPKs) have been correlated to downstream effects of cellular oxidative stress and may 
be involved in the apoptosis pathway. These MAPKs include extracellular signal 
regulated kinases (ERKs), p38 kinase, and the c-Jun N-terminal kinases (JNKs) [65]. 
ROS exposure has been found to induce the phosphorylation activity of p38 and increase 
apoptosis in cardiomyocytes [66]. ERKs are also involved in the cellular response to 
oxidative stress, as ROS exposure leads to up-regulation of ERKs [67]. In addition, these 
kinases play a role in the cascade of signals upstream from mitochondrial cytochrome-c 
release [68]. JNKs are other enzymes that are also involved in the cellular stress response, 
although it has been reported that JNK can act in a pro- or anti-apoptotic manner, 
depending on the cell type, nature of the stimulus, and duration of activity [69]. The 
transcriptional pathway of NF-κB is another signaling route involved in the cellular 
response to oxidative stress. Epigallocatechin gallate is able to cytoprotect against I/R 
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induced injury when administered to rats, and has also been found to inhibit the NF-κB 
pathway.  
Due to the complexity of I/R injury, a multitude of treatment strategies have been 
investigated. Although anti-oxidant treatment has seen some success in animal models in 
attenuating I/R injury as described earlier, the results have been less conclusive in clinical 
trials. Some investigators have observed protective effects by direct antioxidants such as 
vitamin E against I/R injury [70-71], while other investigators did not observe such 
results [46, 72-73]. Superoxide dismutase has also been shown to improve graft 
acceptance in patients receiving renal transplants [74], but failed to provide any benefit in 
myocardial function when administered to patients who had experienced myocardial 
infarction [75]. Despite equivocal experimental results such as these, there is a 
considerable data that supports the significance of oxidative stress in I/R injury and the 
importance of antioxidants in protecting against this type of damage. Findings from the 
animal studies discussed earlier in addition to the positive results from various clinical 
trials warrant further investigation into the use of antioxidants as well as compounds that 







1.3 – CAFFEIC ACID PHENETHYL ESTER (CAPE) 
 
 
CAPE is a naturally occurring antioxidant compound produced by plants and 
found in honeybee propolis. Propolis is a resinous substance used by bees to seal spaces 
in the hive. Natural medicine practitioners from many cultures have recommended 
propolis as a remedy for inflammation, intestinal disorders and burns. Flavonoids derived 
from propolis have been shown to protect against I/R injury in animal models in a variety 
of organs [76-78]. The components of propolis include resins from various plants and 
wax produced from the body of the bees. Propolis is typically aromatic and has a color 
ranging from light green to dark brown, depending on the types of constituents that 
comprise it. Chemical analysis estimates that propolis contains over 300 different 
compounds and is composed of primarily resin (50%), wax (30%), essential oils, (10%) 
pollen (5%) and other organic compounds (5%) [79-80]. The components of propolis 
vary depending on the source of plant resin, climate and other environmental conditions. 
CAPE has been found to be concentrated in propolis located in temperate climates. 
CAPE has the form of an off-white powder with molecular weight 284.31 and 
empirical formula C17H16O4. CAPE is soluble in most organic solvents including ethyl 
acetate, DMSO, ethanol and methanol. The structure of CAPE is shown in Figure 1.2. 
CAPE is susceptible to photo-oxidation and should be protected from light when stored 




















Numerous animal studies have investigated CAPE as a protectant against I/R 
injury. When 50 µM/kg of CAPE was administered to rats prior to a coronary occlusion, 
it was found that myocardial infarct size was reduced from an average of 23 cm
3
 for 
control rats to an average of 9  cm
3 
for CAPE treated rats [81]. Another study reports that 
rats treated with 1 µg/kg of CAPE prior to coronary occlusion resulted in significantly 
fewer incidents of ventricular fibrillation and lower mortality rates than control rats [82]. 
CAPE was administered to rats at 10 µM/kg concentration prior to an intraocular 
ischemic event and it was found that the CAPE treated rats had significantly fewer 
apoptotic cells in the retina than did non treated rats [83]. The effects of CAPE were also 
investigated in rats that experienced I/R injury of the kidneys. It was reported that CAPE 
treated rats experienced significantly reduced amounts of tubular necrosis in the kidneys 
than did rats that were treated only with negative control [84]. CAPE has also been 
shown to be protective in other types of I/R injury including ischemic episodes in the 
spinal cord, testis and intestines [85-87].  
CAPE is well documented as being an inhibitor of pro-inflammatory mediators. 
Natarajan et al. report that CAPE is a specific inhibitor of NFκB activation [88], a result 
that is consistent with findings from numerous other studies [89-92]. CAPE’s anti-
inflammatory properties have also been attributed to its activity as an inhibitor of tumor 
necrosis factor alpha (TNF-α) and Il-8 both in vitro and in vivo [93-95]. Other pro-
inflammatory mediators that CAPE has been shown to inhibit include Il-1 alpha and beta, 
and Il-6 [95-97]. CAPE has also been implicated as an inhibitor of cyclooxygenase-2 
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both in vitro and in vivo, another possible mechanism through which CAPE exerts its 
anti-inflammatory activity [65, 98].   
CAPE has received recent interest as an anti-tumor agent and has been found to 
inhibit growth of a number of tumor cell lines [99]. Grunberger et al. report that CAPE 
exerts higher cytotoxicity in tumor cells than in analogous normal cells [100]. CAPE is 
also cited to have anti-metastatic action on various tumor cell lines due to its inhibition of 
matrix metalloproteinase-2 and -9 [101]. CAPE is implicated in inducing apoptosis in 
human pancreatic cancer cells, human prostate adenocarcinomas, and in inhibiting 
proliferation of C6 glioma cells as well among others [99, 102-105] . 
The activity of CAPE as a potent radical scavenger and antioxidant is well 
documented. Chen et al. reported a 57% radical inhibition of 0.1 mM 1,1-diphenyl-2-
picrylhydrazyl (DPPH) by 20 µM CAPE. It was also found that CAPE inhibited lipid 
oxidation by 18 hours over control in the Rancimat antioxidant assay [106]. Göcer et al. 
report similar concentrations for CAPE in DPPH inhibition, in addition to significant 
reducing ability in the ferric ion reducing power and cupric ion reducing power assays 
[107]. The antioxidant ability of CAPE is thought to be attributed to the two hydroxyl 
groups located on the catechol ring of the compound [108]. The antioxidant and radical 
scavenging properties of CAPE have also been investigated in the context of cellular 
protection. Wang et al. report CAPE is a protective against the oxidative damage caused 
by 2,2'-azobis(2-methylpropionamidine) dihydrochloride (AAPH) and H2O2 in multiple 
cellular structures. Specifically, CAPE showed significant inhibitory effects against lipid 
peroxidation, DNA strand breakage and protein fragmentation when compared to control 
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[109]. CAPE has also shown protection against isoniazid induced oxidative stress in red 
blood cells and against 12-O-tetradecanoylphorbol 13-acetate (TPA) induced oxidative 
stress in HeLa cells [110-111]. Our laboratories have also previously shown CAPE to be 
cytoprotective against menadione induced oxidative stress in human umbilical vein 
endothelial cells (HUVEC) [112]. It is likely that this antioxidant activity contributes to 
the ability of CAPE to protect against I/R injury to some degree, since the generation of 
ROS is one of the primary mechanisms of damage through which I/R injury occurs. If 
CAPE is able to scavenge these ROS prior to their interaction with cellular structures the 
damage caused may be attenuated.  
The mechanism through which CAPE is able to exert its beneficial properties is 
not fully understood. While it is believed that antioxidant activity is important in the 
treatment of I/R injury, the nature of the injury is complex and many pathways are 
affected. When a stress event such as I/R occurs, there are cellular defense mechanisms in 
place to respond to the stressor. Activation of these stress response systems prior to injury 
has shown to be effective in attenuating the damage caused. Ischemic preconditioning is 
one such method to activate these stress response enzymes and involves subjecting tissue 
to a short period of hypoxia prior to the ischemic event. Ischemic preconditioning has 
been reported to be consistently effective in reducing infarct size in myocardial I/R 
injuries in various animal models [113]. Preconditioned tissues have also been shown to 
have fewer ROS released and reduced amount of apoptotic cells following reperfusion 
when compared to non-preconditioned controls [114]. Heme oxygenase-1 (HO-1) is one 
such stress response enzyme that is up-regulated during ischemic preconditioning and has 
 17 
been implicated as a cytoprotectant against the oxidative stress caused by I/R injury 
[115]. CAPE has been shown to be a strong inducer of HO-1 expression. CAPE’s 
cytoprotective properties may very well be a combination of its antioxidant properties 



















1.4 – HEME OXYGENASE-1 
 
 
Heme oxygenase-1 (HO-1) is a stress response enzyme that is induced in response 
to harmful stimuli such as ROS, hypoxia and acidosis [116-117]. HO-1 induction in 
response to ROS induced oxidative stress has been attributed to transcriptional activation 
by Nuclear factor (erythroid-derived 2)-like 2 (Nrf-2). Under normal conditions, Nrf-2 is 
bound in the cytosol to Kelch like-ECH-associated protein 1 (Keap1). ROS induced 
oxidative stress promotes the dissociation of Nrf-2 from Keap1, allowing it to move into 
the nucleus and bind to the promoter region of the antioxidant response element (ARE); 
inducing the transcription of HO-1 [118-119].  
Initially, HO-1 was recognized as the enzyme involved in the metabolism of 
heme. HO-1 breaks down heme into equimolar amounts of carbon monoxide (CO), 
biliverdin, and iron (Fe), and is encoded by the heme oxygenase 1 gene (HMOX-1). 
However it has been recently discovered that upon induction, HO-1 exhibits broad 
cytoprotective properties [120-122]. Our interest in HO-1 revolves around the enzyme 
system’s involvement in protection against I/R injury and oxidative stress [123-126]. 
Amersi et al. reported that upregulation of HO-1 prior to an ischemic event protected rat 
livers from reperfusion injury [127]. Katori et al. found that overexpression of HO-1 
protected rat hearts from I/R injury [128]. I/R injury induced from transplantation 
procedures also appear to be attenuated by the induction of HO-1 expression [129-131].  
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A number of possible explanations for HO-1’s protective activity have been 
offered. Under oxidative stress conditions, heme may be released from hemoproteins 
allowing them to catalyze the production of free radicals through Fenton chemistry [132]. 
The ability of HO-1 to catabolize free heme and therefore preventing it from inducing 
radical production is one possible explanation for the cytoprotection against oxidative 
stress that HO-1 provides. Many of the studies investigating the cytoprotection 
mechanism of HO-1 have done so in the context of apoptosis [118]. HO-1 induction has 
been found to inhibit TNF-mediated apoptosis [133] through cooperation with the anti-
apoptotic actions of NF-κB signaling [134]. HO-1 has also been reported to act through 
the akt/PI3K transduction pathway, inducing the expression of Bcl-xl and Bcl-2, two anti-
apoptotic genes with activity in the mitochondria [128]. In addition to the enzymatic 
action of HO-1, there is evidence that the end products of HO-1 activity; CO, Fe, and 
biliverdin, may also contribute to the cytoprotective effects. The presence of CO leads to 
the degradation of the p38α isoform while maintaining the anti-apoptotic isoform p38β, 
suppressing caspase activation and apoptosis [135]. Biliverdin can be converted to 
bilirubin, a potent antioxidant compound [136]. Iron has also been linked to suppression 
of TNF mediated apoptosis through its induction of ferritin, an iron sequestering 
compound [137]. To further study the involvement of HO-1, investigators have utilized 
compounds to inhibit the expression of HMOX-1 to determine whether or not 
cytoprotection is compromised. Inhibition of HMOX-1 by small interfering RNA 
(siRNA) has been shown to remove the cytoprotective effect initially provided by HO-1 
against in vivo I/R injury [124, 138] as well as in vitro oxidative stress [138-139]. The 
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addition of tin protoporphyrin IX, another inhibitor of HO-1, has likewise shown removal 
of cytoprotection both in vivo [140] and in vitro [141]. The results from these studies 
suggest that HO-1 activity is necessary for cytoprotection against the oxidative stress and 
inflammatory response resulting from I/R injury. The pathways discussed earlier are 
correlated with the induction of HO-1 and are all possible mechanistic explanations for 
the cytoprotection provided. There is however, no single definitive pathway fully 
accounting for the manner in which HO-1 provides protection against oxidative stress, 
though there is strong correlation between induction of HO-1 and cytoprotective activity.  
Compounds that are able to up-regulate the expression of HO-1 have garnered 
interest as potential therapeutic agents for combating the effects of I/R injury. The up-
regulation of HMOX-1 in HUVEC has been observed following incubation of CAPE, 
and is consistent with reports in the literature concerning the relationship between 
cytoprotection and HMOX-1 expression. In addition, when suppressing HO-1 with tin 
protoporphyrin IX, it was found that the cytoprotection against menadione provided by 









Chapter 2 – Synthesis of Caffeic Acid Phenethyl Amide (CAPA) and 
Fluorinated Derivatives 
 
2.1 – INTRODUCTION 
 
 We believe that CAPE is a promising therapeutic compound due to the 
effectiveness it has shown in combating I/R injury in animal models and for its 
cytoprotective activity against oxidative stress both in vivo and in vitro; properties that 
were discussed earlier. We have previously conducted a number of studies aimed at 
investigating CAPE’s properties. Wang et al. treated HUVEC with 5 µg/ml of CAPE 
prior to exposing the cells to 25 µM menadione and was able to observe 60% cell 
viability vs the 8% viability of the untreated cells  [112]. It was seen that CAPE highly 
upregulated the HMOX-1 gene and also significantly increased the amount of HO-1 
protein in HUVEC as well [142]. Despite showing significant activity, it was found that 
CAPE is readily hydrolyzed in plasma (t1/2 = 0.35h at 37 °C) [143] and that it is removed 
quickly from circulation (t1/2 = 26 minutes) [144].  
Structural modification of CAPE was done previously in the form of fluorine 
introduction to the catechol ring at various positions in efforts to promote stability of the 
compound [112]. CAPE fluorinated at the 6’ position (FCAPE) was found to exhibit 
similar cytoprotective properties against menadione in HUVEC to CAPE. FCAPE was 
then tested for stability in rat plasma and in circulation in male Sprague-Dawley rats. 
FCAPE showed a 1.31 fold increase in half-life at 37°C in rat plasma over CAPE and no 
significant difference in circulation half-life (P > 0.05) [143-144].  
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 The purpose of this research project was to significantly increase the circulation 
half-life of CAPE without compromising its desirable cytoprotective properties. FCAPE 
derivatization was successful such that the cytoprotective activity against menadione 
induced oxidative stress was maintained, however the compound showed no 
improvements in circulation half-life. We hypothesized that the activity of esterase 
enzymes in circulation was responsible for the rapid decomposition of CAPE. We 
therefore decided to synthesize CAPA, a CAPE derivative that contained an amide bond 
in place of the ester. The lack of an ester bond would prevent the decomposition of the 
compound by esterases in the serum. The structures of CAPA and the CAPA derivatives 
are shown in Figure 2.1. Hydroxyl groups were methylated at various positions on the 
catechol ring. This was done to determine the effect that the hydroxyls had on 
cytoprotective activity. Fluorine was also placed at varying positions on the catechol ring 
to see if cytoprotective activity would be affected.  
Fluorination of potential drug candidates is a popular practice that has seen much 
success in imparting desirable properties to compounds. Fluorine is the most 
electronegative element in the periodic table and has a strong electron withdrawing effect 
on neighboring functional groups. The inductive effect of fluorine is significant and can 
alter a number of physicochemical properties such as affecting the pKa of acidic groups 
as far as 4 carbons away [145]. Fluorine has been introduced to compounds to improve 
metabolic stability and to enhance potency. The C-F bond is more resistant to attack than 
the C-H bond and may prevent oxidative metabolism. Substitution may also alter the 
conformation or electrostatic properties of the compound. Fluorine substitution 
significantly enhanced the potencies of the drug candidates that eventually became the 
marketed drugs Ezetimibe® and Sitagliptin®. Enhanced duration of action was also seen 
following a fluorine substitution in a candidate compound that eventually became 
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Aprepitant®. Another example is that of Taranabant®, a drug that had reduced potential 
for covalent protein binding compared to a non-fluorinated derivative [146-147]. We 
were interested in fluorinating the catechol ring because of its purported importance in 
radical scavenging and cytoprotective activity [148-149]. This modification was done in 
attempt to improve the protective activities of the CAPA derivatives.  
CAPA has been previously synthesized and described [150-151]. Previous work 
on CAPA has described its ability to act as an antioxidative against lipid peroxidation 
[152] as well as a potential anti-inflammatory agent through its inhibition of 5-
lipoxygenase [151]. CAPA has also been shown to exhibit significant radical scavenging 
activity using a 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay [150] Although various 
CAPA analogues have been investigated for both radical scavenging activity as well as α-
glucosidase inhibition [153] no catechol ring fluorinated CAPA analogs have been 
studied.  The cytoprotectant ability of CAPA in vitro has also not been previously 































































2.2 – MATERIALS AND METHODS 
 
2.2.1 – Materials and Instrumentation 
 
The reagents chloroacetyl chloride, phenethylamine, chloro-tert-butyldimethyl-
silane (TBDMSCl), 3,4-dihydroxybenzaldehyde, 2-fluoro-4,5-dimethoxy-benzaldehyde, 
3-fluoro-4-methoxy-benzaldehyde, 3-fluoro-4-hydroxy-5-methoxy-benzaldehyde, tetra-
butyl-ammonium-fluoride (TBAF), hydrogen peroxide, and boron tribromide were 
purchased from Sigma Aldrich (St Louis, MO) and used without further purification.  All 
solvents were distilled prior to use. Nuclear magnetic resonance (NMR) spectroscopy 
was performed with a Varian Unity+ 300 (300 MHz). Melting points were obtained using 
a Buchi B-540 apparatus and are uncorrected. Mass spectrometry services were provided 
by the Mass Spectrometry Facility at the University of Texas at Austin. Carbon, 
hydrogen, and nitrogen (CHN) elemental analysis was conducted by Quantitative 
Technologies Inc (Whitehouse, NJ). HPLC was performed on a Varian Prostar 320 
system. Purity of the final compounds was assessed by both normal and reverse phase 
HPLC at λ=320 nm. Normal phase isocratic elution was conducted with a Varian 
Microsorb 100-5 Silica HPLC column (250x4.6 mm) running for 30 minutes at 75% 
ethyl acetate and 25% hexane. Reverse phase isocratic elution was conducted with an 
Alltech Partisil C8 HPLC column (250x4.6 mm, 5 µm) running for 30 minutes at 60% 





2.2.2 – General Synthesis Pathway 
 
CAPA and five additional fluorinated amide analogues of CAPE were prepared 
using a Wittig coupling approach.  The known chloroacetamide 1 [154-155] was reacted 
with triphenyl phosphine to give the phosphonium chloride 2 (Figure 2.2).  Wittig 
coupling of 2 with unprotected hydroxybenzaldehydes 3a-e (Figure 2.3) proved 
problematic, in contrast to previous studies employing the analogous ester phosphonium 
chloride [112]. Thus, the hydroxybenzaldehydes 3a-e, which were either commercially 
available or obtained via demethylation of the corresponding methoxybenzaldehydes 
with boron tribromide, were first transiently protected as the t-butyldimethylsilyl ethers 
by treatment with TBDMSCl and imidazole prior to Wittig coupling (Figure 2.3). The 
resulting α,β-unsaturated amides were subjected to deprotection with TBAF, to afford 
CAPA and the desired amides 4b-e in modest overall yields. The 
dimethoxybenzaldehyde 3f was used directly in the Wittig coupling to afford 4f in 
reasonable yield.  With the exception of amide 4e which was isolated as a ~3:1 mixture 
of (E)-/(Z)- isomers after column chromatography, the amides 4 were obtained as >90% 










































Compound R2 = R3 = R4 = R5 = Yield
a 
4a (CAPA) H H H OH 14% 
4b F H H OH 7% 
4c H OH H F 15% 
4d H OMe H F 22% 
4e H H H F 8%
 b
 
4f F H Me OMe 63%
 c 
 
a. Isolated overall yield from benzaldehyde 3 after column chromatography and        
recrystallization.  
 b.  Isolated as ~3:1 mixture of (E)-/(Z)-isomers.  
 c.  Step 2 only. 
 






















1.  TB DM SC l, im idazo le, D M AP (cat)
    D M F, rt, 1 h
2 .  2 , C s2CO 3 
     d ioxane/C HC l3, 60 °C , 18  h
3 .  TB AF
     TH F, 0  °C , 5 m in
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2.2.3 – Experimental 
 
2-Chloro-N-phenethyl-acetamide (1).  To a solution of phenethylamine (20 mmol, 2.52 
mL) in CH2Cl2 (40 mL) was added K2CO3 (24 mmol, 3.32 g).  Chloroacetylchloride (22 
mmol, 1.75 mL) was slowly added to the reaction mixture. The reaction mixture was 
stirred at 45 ˚C under argon for 18 hours. The mixture was diluted with CH2Cl2, washed 
with water and brine, and then dried over Na2SO4. The resulting solution was 
concentrated under a rotary evaporator and the resulting solid filtered to give 2.93 g of 
white crystals (74% yield); mp 63.6-64.6 ˚C (lit [154], 65 °C);  
1
H-NMR spectrum 
matches literature [154]. 
 
  
Phenethylcarbamoylmethyl-triphenylphosphonium chloride (2).  To a solution of 
triphenylphosphine (18.9 mmol, 4.96 g) in THF (50 mL) was added 2-chloro-N-
phenethylacetamide 1 (12.6 mmol, 2.5g.  The mixture was stirred at 85˚C for 72 hours 
under argon. The reaction mixture was diluted with diethyl ether and filtered, giving 4.75 
g of white solid (82% yield); mp 220.9–222.8 ˚C; 1H-NMR δ (CDCl3): 2.67 (2H, t, J = 
8.1 Hz), 3.31 (2H, q), 5.05 (2H, d, J = 14.4 Hz), 7.15-7.25 (5H, m), 7.59-7.68 (5H, m), 






General Procedure for the Demethylation of Benzaldehydes 
 
2-Fluoro-4,5-dihydroxy-benzaldehyde. 2-Fluoro-4,5-dimethoxy-benzaldehyde (4 
mmol, 736.64 mg) was dissolved in 10 mL of CH2Cl2. The mixture was placed in a -78˚C 
acetone and dry ice bath and 10 mL of a 1 M solution of BBr3 in CH2Cl2 was added 
slowly under argon. The reaction mixture was allowed to warm to room temperature and 
stirred for 18 hours. Methanol was added to the resulting mixture, and the solvent 
evaporated. This process was repeated three times. Column chromatography (5:1 
CH2Cl2/EtOAc) afforded 590 mg (94.5% yield) of  2-fluoro-4,5-dihydroxy-benzaldehyde 




General Procedure for the Wittig reaction 
 
3-(3,4-Dihydroxy-phenyl)-N-phenethyl-acrylamide (4a, CAPA).  A mixture of 3,4-
dihydroxybenzaldehyde (3 mmol, 414.36 mg), imidazole (9 mmol, 612.72 mg), 
TBDMSCl (9 mmol, 1356.48 mg), and DMAP (0.3 mmol, 36.65 mg) were dissolved in 5 
mL of DMF and allowed to react at room temperature under argon for 1 hour. The 
reaction mixture was extracted with diethyl ether, washed with deionized water, and then 
dried over Na2SO4. Column chromatography (2% EtOAc in hexane) of the residue after 
evaporation of the solvent afforded 540 mg of the protected benzaldehyde, which was 
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combined with the phosphonium chloride 2 (1.8 mmol, 828 mg) and Cs2CO3 (3.9 mmol, 
1651.65 mg) and then 5 mL of dioxane and 5 mL of CHCl3. The resulting mixture was 
heated to 60˚C and for 18 hours. Extraction was performed with CHCl3, and the reaction 
mixture was washed with water and dried over Na2SO4. Column chromatography (3:1 
hexane/EtOAc) gave 550 mg of yellow oil.  The oil was dissolved in 5 mL of THF and 
TBAF (2.5 mL, 1M in THF) was then added and the mixture was stirred for 5 minutes at 
0˚C. The reaction mixture was concentrated on a rotary evaporator and subjected to 
chromatography on a silica gel column (4:3 EtOAc/hexane). Recrystallization (CH2Cl2 
and hexane) afforded 115 mg of 4a as a white solid: mp 145 ˚C (lit [150], 138-140 ˚C);  
1
H NMR matches literature [150]; 
13
C NMR (CDCl3) δ 35.48, 41.09, 113.89, 115.30, 
117.17, 120.95, 126.2, 127.13, 128.35, 128.65, 139.39, 141.07, 145.56, 147.60, 168.14. 
CI-MS m/z 284 (MH
+
, 100). HRCI-MS: Calculated for C17H18NO3; 284.1287. Found: 
284.1288. 
1
H NMR spectra is shown on Figure 2.3. 
13
C NMR spectra is shown Figure 
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The following compounds were prepared following the procedure described above: 
 
3-(2-Fluoro-4,5-dihydroxyphenyl)-N-phenethyl-acrylamide (4b).  Recrystallization 
(CH2Cl2 and hexane) afforded 80 mg of 4b as a white solid: mp 145 ˚C;  
1
H NMR (d6-
DMSO) δ (ppm): 2.77 (t, J = 6.9 Hz, 2H), 3.39 (q, J = 6.6 Hz, 2H), 6.40 (d, J = 15.9 Hz, 
1H), 6.60 (d, J = 12.3 Hz, 1H), 6.91 (d, J = 7.8 Hz, 1H), 7.28 (m, 5H), 8.18 (s, 1H), 9.17 
(s, 1H), 9.89 (s, 1H); 
13
C NMR (d6-DMSO) δ: 35.44, 41.11, 102.81 (JC-F = 26 Hz), 113.07 
(JC-F = 5 Hz), 113.29, 119.27 (JC-F = 6 Hz), 126.20, 128.35, 128.64, 133.36, 139.37, 
142.09, 148.67 (JC-F =11.55 Hz), 155.77 (JC-F = 243 Hz), 167.88; CI-MS m/z 302 (MH
+
, 
100). HRCI-MS: Calculated for C17H17NO3F; 302.1192. Found: 302.1194. 
1
H NMR 
spectra is shown on Figure 2.6. 
13
C NMR spectra is shown Figure 2.7. Normal and 
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3-(3-Fluoro-4,5-dihydroxyphenyl)-N-phenethyl-acrylamide (4c).  Recrystallization 
(CH2Cl2 and hexane) afforded 135 mg of 4c as a white solid: mp 154 ˚C;  
1
H NMR (d6-
DMSO) δ (ppm): 2.76 (d, J = 7.2 Hz, 2H), 3.39 (d, J = 6.6 Hz, 2H), 6.36 (d, J = 15.6 Hz, 
1H), 6.81 (d, J = 6 Hz, 1H), 6.86 (s, 1H), 7.23 (m, 5H), 8.09 (t, J = 5.1 Hz, 1H), 9.46 (s, 
1H), 9.71 (s, 1H); 
13
C NMR (d6-DMSO) δ: 35.43, 41.1, 106.41 (JC-F = 20 Hz), 110.59, 
118.79, 126.10, 126.22, 128.36, 128.64, 135.23, 139.34, 140.06, 147.57 (JC-F = 6 Hz), 
152.28 (JC-F = 238 Hz), 167.67; CI-MS m/z 302 (MH+ , 100). HRCI-MS: Calculated for 
C17H17NO3F; 302.1192. Found: 302.1188. 
1
H NMR spectra is shown on Figure 2.9. 
13
C 
NMR spectra is shown Figure 2.10. Normal and Reverse phase HPLC chromatograms are 
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3-(3-Fluoro-4-hydroxy-5-methoxyphenyl)-N-phenethyl-acrylamide (4d).  An 
additional column chromatography purification (1:1.5 EtOAc/hexane) to remove traces of 
the Z isomer, afforded 100 mg of 4d as a white foam: 
1
H NMR (CDCl3) δ (ppm): 2.91 (t, 
J = 6.9 Hz, 2H), 3.68 (q, J = 6.2 Hz, 2H), 5.68 (s, 1H), 5.82 (s, 1H), 6.20 (d, J = 15.4 Hz, 
1H), 6.79 (s, 1H), 6.65 (dd, J = 1.6 Hz, J = 10.8 Hz, 1H), 7.28 (m, 5H), 7.50 (d, J = 15.4 
Hz, 1H); 
13
C NMR (CDCl3) δ: 31.92, 37.13, 52.74, 102.72, 104.76 (JC-F = 19 Hz), 
115.81, 122.65 (JC-F = 9 Hz),122.87, 125.00, 125.09, 131.72 (JC-F = 14 Hz), 135.13, 
136.53, 144.69 (JC-F = 6 Hz), 147.02 (JC-F = 242 Hz), 162.22; CI-MS m/z 316 (MH
+
, 
100). HRCI-MS: Calculated for C18H19NO3F; 316.1349. Found: 316.1351. 
1
H NMR 
spectra is shown on Figure 2.12. 
13
C NMR spectra is shown Figure 2.13. Normal and 















Figure 2.12 – 
1













Figure 2.13 – 
13

























3-(3-Fluoro-4-hydroxyphenyl)-N-phenethyl-acrylamide (4e).  This process afforded 





(CDCl3) δ (ppm) major isomer: 2.91 (t, J = 6.9 Hz, 2H), 3.68 (q, J = 6.1 Hz, 2H), 5.66 (s, 
1H), 6.18 (d, J = 15.6 Hz, 1H), 7.00 (t, J = 8.5 Hz, 1H), 7.12 (d, J = 8.5 Hz, 1H), 7.18 (d, 
J = 1.8 Hz, 1H), 7.28 (m, 5H), 7.52 (d, J = 15.6 Hz, 1H); 
13
C NMR (CDCl3) δ: 35.80, 
41.30, 114.85 (JC-F = 19 Hz), 118.31, 118.66, 125.50, 126.95 (JC-F = 20 Hz), 127.18, 
128.92, 128.99, 138.89, 140.85, 146.99 (JC-F = 14 Hz), 151.86 (JC-F = 241 Hz), 167.13; 
CI-MS m/z 286 (MH
+
, 100). HRCI-MS: Calculated for C17H17NO2F; 286.1243. Found: 
286.1242. 
1
H NMR spectra is shown on Figure 2.15. 
13
C NMR spectra is shown Figure 















Figure 2.15 – 
1












Figure 2.16 – 
13

























3-(2-Fluoro-4,5-dimethoxyphenyl)-N-phenethyl-acrylamide (4f).  Recrystallization 
from EtOAc and hexane gave 48 mg of 4f as white crystals: mp 149 ˚C; 
1
H NMR 
(CDCl3) δ (ppm): 2.92 (t, J = 6.9 Hz, 2H), 3.68 (q, J = 6.5, 2H), 3.88 (d, J = 8.7, 6H), 5.90 
(bs, 1H), 6.38 (d, J = 15.6 Hz, 1H), 6.64 (d, J = 12.0, 1H), 6.90 (d, J = 7.20 Hz, 1H), 7.29 
(m, 5H), 7.66 (d, J = 15.6 Hz, 1H); 
13
C NMR (CDCl3) δ 35.93, 41.09, 56.53 (JC-F = 9.96 
Hz), 100.45 (JC-F = 28 Hz), 110.54 (JC-F = 4 Hz), 114.01 (JC-F = 13 Hz), 121.15 (JC-F =7 
Hz), 126.77, 128.99 (JC-F = 11 Hz), 134.03, 139.15, 145.67, 151.41 (JC-F = 10 Hz), 156.54 
(JC-F = 248 Hz), 166.40; CI-MS m/z 330 (MH
+
, 100). HRCI-MS: Calculated for 
C19H21NO3F; 330.1505. Found; 330.1506; Elemental analysis calculated for 
C19H20NO3F: C, 69.29; H, 6.12; N, 4.25. Found: C, 69.03; H, 6.12; N, 4.21. 
1
H NMR 
spectra is shown on Figure 2.15. 
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2.3 – DISCUSSION AND CONCLUSIONS 
 
Caffeic Acid Phenethyl Amide and five catechol ring fluorinated analogues were 
synthesized, purified and characterized by mass spectrometry, 
1
H NMR and 
13




















Chapter 3 – Cytoprotective Activity of CAPA and CAPA derivatives in 
HUVEC 
 
3.1 – INTRODUCTION 
 
Endothelial cells comprise the inner layer of arteries, veins and capillaries and 
play a key role in the propagation of I/R injury [156]. In addition to providing a 
protective barrier between the lumen and the smooth muscle of a blood vessel, these cells 
contribute to regulation of immune cells, blood flow and overall function of the tissue 
being perfused. The endothelium is also important in modulating the inflammatory 
response that occurs following an I/R episode [157-158]. Upon reperfusion following an 
ischemic insult, these endothelial cells produce the previously discussed ROS rapidly in 
large amounts [159-160]. Major sources of ROS production from the endothelium have 
been reported to be from cytosolic xanthine oxidase and from complexes I and III of the 
electron transport chain [161-162]. Recruitment of neutrophils and other immune cells 
are also responses to I/R injury and can exacerbate the damage caused by the endogenous 
ROS. Injury to the endothelium can result in interferences with the performance of 
homeostatic functions such as maintenance of local blood flow, control of fluid exchange 
with the surrounding tissues and regulation of immune cells. If the damage caused is 
severe enough, endothelial dysfunction can manifest as inadequate perfusion, leak of 
vascular fluids or inflammation [163]. Since these endothelial cells are the first to 
experience the consequences of I/R injury, they serve as an appropriate model for 
studying the effects of the oxidative stress that follows reperfusion. Damage to the 
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endothelium has also been shown to correlate with function of neighboring tissues [164-
165].  
Human Umbilical Vein Endothelial Cells (HUVEC) were chosen as a model cell 
line because of the previously discussed significance of the endothelium in I/R injury. 
Endothelial cells are both targets and producers of ROS following an ischemic event and 
therefore are useful for studying the effects of cytoprotectants against oxidative stress. 
HUVEC are harvested from umbilical cords and pooled before distribution to minimize 
variability. HUVEC have been used extensively in a wide array of research activities and 
have also been utilized in studies simulating I/R conditions in vitro [166-168]. Hydrogen 
peroxide was employed as the inducer of oxidant stress in this study. H2O2 is commonly 
used as an exogenous stressor and has been used to induce oxidative damage and 
apoptosis in a variety of cell types in cytoprotection studies [169-173]. H2O2 is also one 
of the ROS produced endogenously by endothelial cells in I/R conditions.  
CAPA and the fluorinated CAPA analogues were synthesized to improve the 
stability of CAPE and to determine whether derivatization affected the desirable 
cytoprotective activity of the parent compound. CAPE has been shown to be a potent 
antioxidant and cytoprotectant against oxidative stress in addition to being a protectant 
against I/R injury. CAPE has also been shown to be a potent inducer of the HMOX-1 
gene and the HO-1 enzyme, a cytoprotective response system discussed earlier [142]. The 
purpose of the following series of experiments was to evaluate the protective activity of 
CAPA and the fluorinated derivatives in comparison to CAPE by way of cytoprotection 





3.2 – MATERIALS AND METHODS 
 
3.2.1 – Materials and Instrumentation 
 
Human umbilical vein endothelial cells (HUVEC) were obtained from Lifeline 
Technologies (Walkersville, MD) and cultivated on 75 cm
2
 1% gelatin coated culture 
flasks using MCDB 131 cell culture media (Invitrogen, Carlsbad CA) supplemented with 
2% fetal bovine serum, ascorbic acid, heparin, VEGF, hydrocortisone bFGF and heparin 
(Lifeline Technologies). The cells were grown to confluency at 37 ˚C in humidified 
atmosphere with 5% CO2. HUVEC were then treated with Trypsin/EDTA and 
subcultivated onto gelatin coated 96 well and 24 well multi-plates and used when 
confluent. Population doubling levels 2 through 5 were used in the described 
experiments. CellTiter-Blue
®
 Blue solution ordered from Promega (Madison WI). 
Spectrophotometry was performed on a Spectramax M2 microplate reader (Molecular 
Devices, Sunnyvale CA). Western blot E-PAGE gels, iBlot apparatus, nitrocellulose 
transfer stacks and loading buffers were ordered from Invitrogen (Carlsbad, CA). Rabbit 
polyclonal HO-1 antibodies were obtained from Assay Designs (Ann Arbor, MI). Mouse 
polyclonal β-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA). Donkey anti-mouse and donkey anti-rabbit secondary antibodies were obtained 





3.2.2 – Cytotoxicity of compounds in HUVEC 
 
CAPE and certain catechol ring-fluorinated CAPE analogs have been reported to 
be cytotoxic to HUVEC at higher concentrations [112]. CAPA and the CAPA derivatives 
were screened along with CAPE for toxicity in HUVEC. Stock CAPE, CAPA, and 
CAPA derivative solutions were dissolved in DMSO then diluted in MCDB 131 tissue 
culture media for use in the assays. Confluent HUVEC were treated with CAPE and the 
amide derivatives for 24 hours at 37 ˚C at concentrations ranging from 10 μM to 60μM. 
Following the 24 hour incubation, the media was replaced with 10 % CellTiter-Blue
®
 
Blue solution (Promega, Madison WI). HUVEC were incubated for 2 hours at 37 ˚C then 
analyzed for fluorescence. The readings were taken at 545 nm excitation and 590 nm 
emission wavelengths on a Spectramax M2 microplate reader (Molecular Devices, 
Sunnyvale CA). Cell viability was calculated from these fluorescence readings and 
compared to the DMSO vehicle control to obtain percent viability. Cell viability less than 
90% of control was considered toxic.   
 
3.2.3 – Cytotoxicity of H2O2 in HUVEC 
 
Hydrogen peroxide is one of the principle reactive oxygen species produced in 
various vascular complications including ischemia reperfusion injury and has also been 
used in other in vitro models as an inducer of oxidative stress in endothelial cells [174-
176]. To determine a suitable dose, HUVEC were treated with H2O2 at concentrations 
ranging from 0.01 mM to 5 mM for one hour. A stock solution of H2O2 (50% w/v, 14.7 
M, Sigma Aldrich) was diluted to 1M with deionized water then subsequently diluted in 
MCDB131 buffer to obtain the desired concentrations. 
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Following the one hour period the culture media was replaced and the cells were 
allowed to recover for 18 hours. Cell viability was assessed with CellTiter-Blue
®
 
following the 18 hour period.  The target dosage was one that reduced cell viability to 
approximately 20% of control.  
 
 
3.2.4 – Cytoprotection Assay 
 
Confluent HUVEC were treated with CAPE and the amide derivatives at 20 μM 
concentration for 5 hours at 37 ˚C. After the 5 hour incubation, the compounds were 
removed from the wells, and the cells were washed twice with MCDB 131 buffer. Stock 
hydrogen peroxide solution (50% w/v, Sigma Aldrich) was diluted in MCDB 131 buffer, 
and incubated in the cells following the buffer wash. HUVEC were incubated in the 
hydrogen peroxide for 1 hour at 37 ˚C. The hydrogen peroxide was then removed. The 
cells were washed once with MCDB 131 media, and were then incubated in complete 
MCDB 131 media for 18 hours at 37 ˚C. Following the 18 hour period, the cells were 
treated with 10% CellTiter-Blue
®
 solution and analyzed for viability. In the dose 
response cytoprotection assay, percent cytoprotection for each compound was calculated 
by subtracting the average fluorescent reading of the negative control (HUVEC treated 
only with DMSO and hydrogen peroxide) from the fluorescent values of each well. This 
was then divided by the average fluorescence of the positive control (HUVEC treated 




3.2.5 – HO-1 expression 
 
HUVEC were treated with 5 µg/ml of CAPE and CAPA for 6 hours. At the 6 hour 
time point, the media was removed and the cells were exposed to 70 µl of lysis buffer. 
The lysis buffer was composed of 50 mM Tris(2-carboxyethyl) phosphine hydrochloride 
(TCEP) and 1x loading solution (Invitrogen, Carlsbad CA). A 48 well E-PAGE gel was 
then loaded with 15µl of the lysis buffer solution and run for 30 minutes. Protein was 
transferred to a nitrocellulose membrane via the iBlot apparatus (Invitrogen, Carlsbad 
CA). Upon successful transfer, the membrane was fixed in a solution of 50% methanol, 
43% water and 7% acetic acid. The membrane was then washed in a solution of 50% 
water and 50% blocking buffer (Licor, Lincoln NE) for one hour. The HO-1 polyclonal 
antibody was diluted 1000x in blocking buffer and introduced to the membrane following 
the blocking phase. Β-actin was used to normalize protein levels and was diluted 25,000x 
in blocking buffer before being introduced to the membrane. The membrane was exposed 
to the primary antibodies for 24 hours at 4 °C. Following this time period, the primary 
antibodies were removed and the membrane was washed 4x with a solution containing 
0.1% tween 20 in PBS. The secondary antibodies were diluted 25,000x in blocking buffer 
and then introduced to the membrane for one hour after the wash. The membrane was 
then washed again with the 0.1% tween in PBS solution and read on the Licor Odyssey ® 
IR scanner using fluorescent antibody imaging for protein quantification. The signal 
obtained for HO-1 was divided by the signal for β-actin so that protein levels were 




3.2.6 – Statistical analysis 
 
Data are reported as means ± standard deviation as a percentage of the control. 
Differences between the groups were first analyzed by ANOVA, and then evaluated by 
the Tukey-Kramer post hoc analysis. O’Brien’s and Bartlett’s tests showed that variances 




















3.3 – RESULTS  
 
3.3.1 – Cytotoxicity of compounds in HUVEC 
 
The results, shown in Figure 3.1 demonstrate that CAPA and amides 4b and 4d-f 
showed no toxicity at any of the tested concentrations. CAPE exhibited cytotoxicity at 40 
μM and 60 μM. The amide 4c showed cytotoxicity at all concentrations.  
 
3.3.2 – Cytotoxicity of H2O2 in HUVEC  
 
Cell viability as compared to control declined steadily as H2O2 concentration was 
increased. The target dosage for the cytoprotection study was one that reduced cell 
viability to approximately 20%. This was achieved with 2 mM H2O2. The results are 













Figure 3.1 - Toxicity of CAPE, CAPA, and CAPA derivatives toward HUVEC. 
Compounds were incubated in HUVEC for 24 hours at 37 ˚C. Cell viability 
was determined by the Alamar Blue assay. Values are reported as a 














































Figure 3.2 - Toxicity of H2O2 in HUVEC. HUVEC were incubated in culture media 
containing the indicated concentration of H2O2 for 1 hour at 37 ˚C.  The 
culture media was replaced and cells were allowed 18 hours to recover, then 










































3.3.3 – Cytoprotection of HUVEC 
 
To evaluate oxidative stress in vitro, we employed a model using H2O2 as the 
inducer of oxidative damage. HUVEC were treated with CAPE or the amide derivatives 
4a-f at 20 μM concentration for 5 hours. The cells were rinsed and the then treated with 2 
mM H2O2.  After 1 hour, the H2O2 containing medium was replaced with cell culture 
media and the cells were allowed to recover for 18 hours.  At the end of the 18 hour 
period, cell viability was assessed with the CellTiter-Blue
®
 Cell Viability assay and 
compared to cells treated only with vehicle and H2O2, as well as with those that were not 
exposed to H2O2. The results are shown in Figure 3.3. CAPA and compounds 4b, 4c, and 
4e exhibited significant cytoprotection against H2O2 when compared to vehicle only pre-
treatment. CAPE was also significantly cytoprotective against H2O2. There was no 
significant difference in cytoprotective activity between CAPE and CAPA (P > 0.05).  
In a dose dependent cytoprotection assay, HUVEC were treated with CAPE and 
CAPA at 1, 5, 20, 40, and 60 µM concentrations prior to the induction of oxidative stress 
with H2O2.  The results are shown in Figure 3.4. The EC50 was calculated for both 
compounds by linear regression using the first 3 data points. The EC50 was found to be 8 









Figure 3.3 - Cytoprotection of HUVEC against 2 mM H2O2 by CAPE, CAPA, and CAPA 
analogues. All compound concentrations were at 20 μM. CAPE, CAPA, 4B, 
4C and 4E all showed significant cytoprotection when compared to untreated 













































Figure 3.4 - Dose response cytoprotection relationship of CAPE and CAPA against 2 mM 
H2O2. Concentrations above 40 µM are cytotoxic for both CAPE and CAPA 
and gave lower cell viability than untreated HUVEC as shown. CAPE and 



































3.3.4 – HO-1 expression 
 
The induction of HO-1 expression was investigated for both CAPE and CAPA. 
Both compounds showed significant increases in HO-1 expression over the DMSO 
control. The western blot is shown in Figure 3.5. The quantified HO-1 expression data in 





















Figure 3.5 – Western blot of HO-1 expression following a 6 hour incubation of 5 µg/ml 
CAPE and CAPA. Protein extractions were performed at 6 hours. 
Fluorescent antibody imaging was used to quantitatively determine protein 















Figure 3.6 – HO-1 induction after a 6 hour incubation by 5 µg/ml CAPE and CAPA in 
HUVEC. Protein extractions performed at 6 hours for all samples. Values 
































3.4 – DISCUSSION AND CONCLUSIONS 
 
Introducing a fluorine group on the catechol ring increases the electronic density 
of the conjugated system, can decrease the interaction with catechol methyltransferase, 
and may also have a significant effect on receptor binding or selectivity [177]. The 
hydroxyl groups on the CAPA catechol may contribute to the antioxidative activity of the 
compound. We were interested in seeing the effect of replacing one of these hydroxyls 
with a fluorine, hydrogen or methoxy group on the cytoprotective activity of the 
compound.    
Prior to evaluating the cytoprotective activity of CAPE and the CAPA derivatives, 
each compound was screened for toxicity in HUVEC. CAPE was found to be toxic at 40 
and 60 μM, in accord with previous studies [112]. There are interesting differences in 
cytotoxicity of the certain amide derivatives when compared to their corresponding ester 
analogues.  Amides 4e and 4f were not cytotoxic at any concentration up to 60 µM, the 
highest concentration examined.  The corresponding ester derivatives were similarly 
reported to be non-cytotoxic at concentrations up to 15 µg/mL (ca. 50 µM).  Amide 4c 
was toxic at all the concentrations tested; similar to the corresponding ester analogue 
[112].  However, whereas CAPE and the esters corresponding to 4b and 4d are cytotoxic 
at concentrations greater than 40 µM, CAPA and the amides 4b and 4d are not cytotoxic 
even at concentrations as high as 60 µM.  The origin of this difference in cytotoxicity 
between CAPE and certain fluorinated CAPE analogues versus CAPA and the 
corresponding fluorinated CAPA analogues is not clear.   
CAPE was significantly cytoprotective against H2O2 induced oxidative stress in 
HUVEC. This was also demonstrated previously in a similar model [109] as well as a 
study which used menadione to generate an oxidative stress [112]. Four of the amide 
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derivatives of CAPE were also found to be significantly cytoprotective. These four 
compounds all contained either one or two hydroxyl groups on the cinnamic acid phenyl 
ring. Although compound 4c proved to be very cytotoxic in HUVEC over a 24 hour 
period, the toxicity is less apparent over a 5 hour incubation time, as the compound was 
found to be significantly cytoprotective against H2O2, and exhibited significantly higher 
cell viability over the vehicle control. While the mechanism behind this cytoprotective 
activity is not completely known, it is suggested that the anti-oxidative and radical 
scavenging properties of the catechol group are correlated with the protection against 
H2O2. The catechols CAPE, CAPA, 4b, and 4c all display cytoprotective effects; 
whereas, the monomethylated and dimethylated analogues 4d and 4f, respectively, were 
not cytoprotective.  The ortho-fluorophenol 4e demonstrated intermediate cytoprotection, 
which may be due to the ability of the ortho-fluorine substituent to stabilize the phenol 
radical formed upon hydrogen atom donation [178]. Interestingly, the structure-activity 
relationship for cytoprotective effect for these amides is quite different from that reported 
for the corresponding esters.[112]  The ester corresponding to 4c is not cytoprotective, 
despite the presence of the catechol functionality, and the ester corresponding to 4e is 
cytoprotective, despite the lack of any free phenolic hydroxyl groups.  In the dose 
dependent cytoprotection assay, a biphasic response was observed for both CAPE and 
CAPA. The cytoprotection percentage increases from 1 µM up to 20 µM of CAPE and 
CAPA, then starts to decline at 40 µM. The drop off in cytoprotection at higher CAPE 
concentration had been attributed to CAPE’s cytotoxicity above 20 µM [179] as indicated 
in Figure 3.1. However, a similar effect is observed for CAPA, even though it is not 
cytotoxic at 40 µM.  It is unclear as to why this phenomenon occurs. 
It is not well understood how cytoprotection is provided by pretreatment with 
these cytoprotective agents. Studies previously performed in our group have shown that 
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the cytoprotective activity of CAPE was correlated with the levels of the heme oxygenase 
1 (HMOX 1) gene expression. CAPE is a potent inducer of the HMOX 1 gene 
transription and has been shown to up-regulate it as much as 8-fold over control [142]. 
Studies have also shown that when heme oxygenase activity is inhibited, the 
cytoprotective effect of CAPE against menadione induced oxidative stress is abolished 
[142]. The findings demonstrate that CAPA is less toxic than CAPE, and that there is no 
significant difference in cytoprotection between the two when tested at 5 and 20 µM 
concentrations against 2 mM hydrogen peroxide. Both CAPE and CAPA treated cells 
were able to significantly induce the expression of HO-1 over control with as little as 1 
hour of exposure time. There were also no significant differences found in HO-1 
expression between cells treated with CAPE and CAPA beyond 2 hours of exposure time. 
These findings suggest that the cells may not need to be continually exposed to CAPE or 
CAPA in order for a protective effect to be induced.  
CAPA and catechol ring-fluorinated derivatives of CAPA were synthesized and 
investigated for cytoprotective activity against hydrogen peroxide induced oxidative 
stress in HUVEC.  All but one of the CAPA derivatives synthesized were non-toxic up to 
the maximally tested concentration, with 4c being toxic at all tested concentrations. The 
results here also show that CAPA, 4b, 4c, and 4e are all significantly cytoprotective in 
this model (P < 0.05). The only two analogs which were not cytoprotective were the 
methylated compounds 4d and 4f. Although the mechanism of cytoprotection is not well 
understood, the antioxidative activity appears to be important as cytoprotection is 
correlated with the presence of free catechol hydroxyl groups. CAPA was less toxic in 
HUVEC when compared to CAPE, however, there was no significant difference found in 
cytoprotection between the two compounds. The lower toxicity exhibited by CAPA 
allows for higher concentrations of the compound when dosing.  
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Chapter 4 – Stability of CAPA in Male Sprague-Dawley Rat Plasma 
 
4.1 – INTRODUCTION 
 
CAPE’s protective activities in vitro and in vivo have been well documented 
despite being labile in serum and in circulation [143]. Attempts to improve upon the 
stability of CAPE led to the synthesis of CAPA and 5 fluorinated derivatives of CAPA. 
Amides are generally associated with higher hydrolytic energies of activation. CAPA is 
also able to avoid hydrolysis via esterase enzymes due to lack of an ester bond. We 
therefore hypothesized that the amide derivatives would exhibit higher stability in serum. 
The previous cytoprotection study against H2O2 induced oxidative stress in HUVEC 
showed that there was no significant difference between CAPE and CAPA in protective 
ability. CAPA was also the most cytoprotective of the synthesized analogues so it was 
chosen as the candidate to be tested for stability alongside CAPE. 
Plasma stability is an important consideration in drug development. Drug 
compounds that exhibit poor stability in plasma present high clearance, short half lives 
and minimized exposure in vivo, possibly resulting in poor efficacy. Extremely rapid 
plasma decompositions can also compromise the establishment of reliable 
pharmacokinetic profiles, since ex vivo hydrolysis of the compound becomes a significant 
variable [180]. Improved plasma stability could mean an extended half-life of the 
compound in vivo, longer exposure times in circulation and potentially increased 
efficacy. The purpose of these experiments was to determine whether amide 
derivatization improved the plasma stability of CAPE.  
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4.2 – MATERIALS AND METHODS 
 
4.2.1 – Materials and Instrumentation 
 
CAPE (≥ 98%) and trans-resveratrol (≥ 98%) were obtained from Cayman 
Chemical (Ann Arbor, MI). CAPA (≥ 95%) was synthesized and characterized 
previously in our laboratories [181]. Heparinized male Sprague-Dawley rat plasma was 
obtained from Innovative Research (Novi, MI). Water used in the experiments was 
passed through a Millipore (Billerica, MA) Milli-Q water purification system (18.2 MΩ). 
HPLC grade methanol was obtained from JT Baker (Mallinckrodt Baker, Phillipsburg, 
NJ). HPLC grade ethyl acetate was from Sigma Aldrich (St Louis, MO). An Agilent 1200 
series HPLC (Santa Clara, CA) was used comprising a 1200 series pump, diode array 
detector, autosampler, and degasser. Separation was achieved with an Agilent ZORBAX 
C18 column (4.6 × 150 mm, 5µm) coupled to a cartridge guard column (4.6 × 12.5 mm) 
of the same material. The column was maintained at 25°C for the duration of the analysis. 
Autosampler temperature was maintained at 4°C. Instruments were controlled by the 
Agilent ChemStation software program. Trans-resveratrol was used as an internal 
standard (IS). It exhibits high absorbance at the λmax of CAPA and CAPE (320 nm), and 
is easily separable from the analyte, decomposition products, and plasma contents with 
the mobile phase and column used. A gradient elution technique was used for the 
separation of both CAPA and CAPE from IS and plasma contents. The mobile phase 
used was ultrapure H2O (solvent A) and MeOH (solvent B). Flow rate was set at 1 
mL/min. The gradient elution program for CAPA and CAPE is described in Table 4.1. 
Detection wavelength was set to 320 nm. 
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CAPA         CAPE 
 
Time (min)  %A %B 
 
Time (min)  %A %B 
0 65 35 
 
0 75 25 
3  65 35 
 
1 75 25 
7  10 90 
 
5 15 85 
8  10  90  
 
8 15 85 
13  65 35 
 
12 75 25 
15  65  35  
 
15 75 25 
 


















4.2.2 – Sample preparation 
 
CAPA, CAPE, and resveratrol working solutions were made in MeOH. Rat 
plasma samples (180 µL) were aliquoted into 1.5 mL microfuge tubes and spiked with 
CAPA or CAPE working solutions (10 µL). Working solutions of CAPA and CAPE were 
made at 0.05, 0.1, 0.2, 1, 2, and 5 mg/mL concentrations for construction of the 
calibration curve. At the time of extraction, 10 µL of resveratrol (400 ug/mL) was added 
to each sample. Ethyl acetate (600 µL) was subsequently added to each sample for 
extraction, followed by 5 minutes of vortexing and 5 minutes of centrifugation at 13,000 
RCF under temperature control (4°C). The ethyl acetate layer was removed and 
transferred to a 2 mL microfuge tube. An additional 600 µL of ethyl acetate was added to 
the remaining plasma sample, and the extraction procedure was repeated. The ethyl 
acetate samples were pooled and evaporated under centrifugal vacuum via the SpeedVac 
Concentrator (Thermo Scientific, Waltham, MA). The dried samples were kept at -20°C 
until analysis. Prior to injection, the samples were reconstituted with 200 µL of MeOH, 
vortexed for 5 minutes, and centrifuged at 13,000 RCF for 2 minutes. The reconstituted 
samples were transferred to 300 µL glass HPLC vials (Agilent, Santa Clara, CA), 









4.2.3 – Method Validation 
 
Analyte response was expressed as CAPA vs resveratrol (IS) or CAPE vs resveratrol (IS) 




Selectivity of the assay was established by utilizing HPLC conditions such that 
analyte quantification was free from interference by endogenous plasma compounds or 
decomposition products.  
 
Calibration curve and linearity 
 
The concentrations of CAPA and CAPE used for modeling response vs 
concentration in rat plasma were 2.5, 5, 10, 50, 100, and 250 µg/mL. Calibration 
standards were analyzed in replicates of 5 per concentration and included 20 µg/mL of 
IS. Linear regression was performed to describe the analyte response vs concentration 




Sensitivity was determined by the limit of detection (LOD) and the lower limit of 
quantification (LLOQ). LOD was defined as the minimum concentration necessary to 
produce a signal to noise ratio of 3:1. The LLOQ is the lowest quantifiable concentration, 
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and is also defined as the lowest concentration on the calibration curve with a signal to 




Intra-day precision was evaluated by spiking blank plasma at 3 concentrations of 
CAPA and CAPE: the lowest and highest concentrations on the calibration curve (2.5 and 
250 µg/mL) and an intermediate concentration (50 µg/mL), and then measuring analyte 
response. Five replicates at each concentration point were analyzed and the results were 
expressed as percent relative standard deviation (%RSD). Inter-day precision was 
evaluated at the same concentration levels (2.5, 50, and 250 µg/mL). Spiked plasma 
samples were processed and analyzed in replicates of five on three separate days. Results 
were expressed in %RSD. Precision determined at each concentration was considered 
acceptable if the %RSD did not exceed 15%, except for the lower limit of quantification 




The accuracy of the method was evaluated as percentage deviation of the mean 
from the true value. Accuracy was determined at three concentration levels (2.5 (LLOQ), 
50, 250 µg/mL). Mean values obtained were considered acceptable if within 15% of the 
true value, except for the LLOQ, where mean values under 20% deviation were accepted. 





Recovery was evaluated as absolute recovery and was calculated by comparing 
analyte peak area from plasma extracted samples to those of the corresponding 
concentrations of unextracted samples. The peak areas of the unextracted samples were 
considered to be 100% recovery, and were obtained by analyzing standards in MeOH that 
were directly injected into the HPLC. Recoveries of CAPA and CAPE were evaluated at 
three concentration levels (2.5 (LLOQ), 50, 250 µg/mL) with three replicates per 


















4.2.4 – Stability Study 
 
This method was developed for the determination of CAPA and CAPE in rat 
plasma and was used to evaluate compound stability. Stability of CAPA in rat plasma 
was determined at 25, 37, and 60 °C and stability of CAPE was determined at 4, 25, and 
37 °C. The concentration of the compounds was evaluated at a minimum of five time 
points for each temperature, with three replicates being analyzed at each time point. The 
decomposition of CAPA and CAPE was determined over a period of 2-5 half lives. The 
purpose of this stability study was to determine the half-life of CAPA and CAPE at each 
respective temperature and to calculate an energy of activation (Ea).  
Blank rat plasma (4.75 mL) was spiked with 0.25 mL of a 2 mg/mL working 
solution of CAPA or CAPE. 190 µL aliquots of the plasma solutions were then placed in 
1.5 mL micro-centrifuge tubes. The tubes were tightly capped and then incubated at the 
intended temperatures. The samples were allowed to incubate at their respective 
temperatures until the time of extraction. Immediately prior to extraction, 10 µL of 400 
µg/mL resveratrol solution was added to each sample. This was subsequently followed by 
the ethyl acetate extraction procedure and HPLC quantification process described earlier. 
These steps were repeated at each time point and were done in triplicate.  
The freeze thaw stability of CAPA was determined by subjecting plasma 
solutions of CAPA to three freeze/thaw cycles (FTC). Plasma solutions of CAPA were 
made in triplicate at 100 µg/mL concentration and frozen at -20°C for 24 hours. These 
solutions were then allowed to thaw unassisted at room temperature, upon which they 
were refrozen at -20°C for another 24 hours. This process was repeated three times. 
Following three FTCs, 10 µL of 400 µg/mL resveratrol was added. The samples were 
extracted using the ethyl acetate extraction procedure described earlier and then 
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quantitatively determined by HPLC. Analyte response of the FTC samples was compared 
to that of plasma samples that did not undergo the three FTCs. The freeze thaw stability 
of CAPA is reported as percent recovery. Long term stability was evaluated by storing 
three replicates of CAPA at 100 µg/mL concentration for 4 weeks at -20 °C. Following 
the 4 week period, 10 µL of 400 µg/mL resveratrol was added. The samples were then 
extracted and quantified on the HPLC. Long term stability is reported as percent 




















4.2.5 – Data analysis 
 
The data from the stability studies for CAPA and CAPE were plotted as the 
natural logarithm of percent remaining vs time. The first order rate constant k was 
obtained from the slope of the linear regression line. The half-life of CAPA and CAPE 
was calculated from the rate constant k obtained from the linear regression lines at each 
of the tested temperatures using the following equation: 
 
                                                        𝑡1/2 =
𝑙𝑛2
𝑘
                                                 (4.1) 
 
The energy of activation (Ea) was calculated for both CAPA and CAPE by fitting the 
obtained rate constants and the corresponding temperatures to the Arrhenius equation: 
 






)                                          (4.2) 
 
k represents the first order decomposition rate constant, A is the pre-exponential factor 
which takes into account frequency of collisions, R is the universal gas constant and T is 







4.3 – RESULTS 
 
4.3.1 – Method Validation 
 
The quantification of CAPE and CAPA was free from interferences by 
endogenous plasma compounds and decomposition products. The chromatograms for 
CAPE and CAPA are shown in Figure 4.1. Calibration curves for CAPA and CAPE were 
constructed by analyzing six concentrations (2.5, 5, 10, 50, 100, 250 µg/mL) of both 
compounds with five replicates assessed at each concentration level. Linear regression 
was performed to describe the relationship between CAPA concentration vs analyte 
response. The following are the linear regression parameters for the calibration curve of 
CAPA: Slope = 0.0235, Intercept = -0.0486, R
2 
= 0.9988, and CAPE: Slope = 0.0217, 
Intercept = -0.0194, R
2 
= 0.9998. The fitted line describes the linear relationship between 
analyte signal and nominal concentration in the range of 2.5 to 250 µg/mL. The LLOQ 
was defined as the lowest concentration on the calibration curve and was 2.5 µg/mL for 
both CAPA and CAPE. Analyte response at the LLOQ was greater than five times the 
blank response. The LOD was determined to be 1 µg/mL for both compounds and was at 
least three times the blank response. Inter-day and intra-day precision for the 
determination of CAPA did not exceed 7.41 %RSD. Precision values for CAPE did not 
exceed 9.34 %RSD. These values were considered acceptable. Accuracy values are 
reported as percent deviation (%Dev). The accuracy of CAPA determination was within 
13.12% of the true value. These values are acceptable within the limits established by the 
FDA guidance. Recovery was calculated as the ratio of analyte response of plasma 
extracted samples to those of unextracted samples. Recovery is reported as absolute 
recovery. Inter-day precision values for CAPA and CAPE are listed in Tables 4.2 and 4.3 
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respectively. Assay qualification parameters are summarized in table 4.4 for both CAPA 



























Figure 4.1 - Representative chromatograms of: (A) Blank rat plasma, (B) Rat plasma 
spiked with 100 µg/mL CAPA and 20 µg/mL IS, (C) Rat plasma spiked with 










                                            Nominal Concentration (µg/ml) 
  2.5 50 250 
 
0.0449 0.915 5.904 
 
0.0448 0.970 5.822 
Day 1 0.0436 1.001 5.793 
 
0.0478 0.965 5.635 
 
0.0470 0.984 6.012 
    
 
0.0512 0.995 6.058 
 
0.0504 1.018 6.045 
Day 2 0.0517 1.038 6.149 
 
0.0518 1.013 6.057 
 
0.0544 1.025 6.100 
    
 
0.0517 1.012 6.048 
 
0.0510 1.012 6.077 
Day 3 0.0456 0.995 5.999 
 
0.0562 1.010 5.918 
 
0.0521 0.993 6.058 
    AVG 0.0496 0.996 5.978 
SD 0.0038 0.030 0.139 
%RSD 7.6021 2.980 2.320 
 
Table 4.2 – Inter-day precision values for CAPA. Analyte responses (CAPA : resveratrol 








                                           Nominal Concentration (µg/ml) 
  2.5 50 250 
 
0.0381 1.130 5.554 
 
0.0339 1.113 5.270 
Day 1 0.0349 1.126 5.435 
 
0.0333 1.135 5.331 
 
0.0348 1.112 5.370 
   
  
 
0.0322 1.164 5.381 
 
0.0304 1.220 5.329 
Day 2 0.0388 1.163 5.128 
 
0.0299 1.143 5.618 
 
0.0355 1.196 5.480 
   
  
 
0.0315 1.056 5.247 
 
0.0300 1.127 5.352 
Day 3 0.0316 1.103 5.369 
 
0.0400 1.117 5.362 
 
0.0335 1.112 5.353 
   
  
AVG 0.0339 1.135 5.372 
SD 0.0032 0.040 0.119 
%RSD 9.3500 3.490 2.222 
 
Table 4.3 – Inter-day precision values for CAPE. Analyte responses (CAPE : resveratrol 

































      
CAPA      
2.5 2.828 ± 0.022 2.87 – 7.41 7.60 13.12 85.2 (6.8) 
50 52.28 ± 0.48 0.96 – 3.31 2.98 4.55 91.1 (4.5) 
250 259.3 ± 1.9 0.71 – 2.39 2.32 3.73 99.8 (1.0) 
      
CAPE      
2.5 2.382 ± 0.003 5.30 – 11.78 9.35 4.74 86.9 (5.1) 
50 50.75 ± 2.33 0.93 – 2.59 3.49 1.51 99.9 (5.5) 
250 248.6 ± 1.7 0.95 – 3.38 2.22 0.56 101.0 (4.1) 
      
Table 4.4 – Intra-day precision, inter-day precision, accuracy and absolute recovery for 















4.3.2 – Stability Study 
 
The natural logarithm (Ln) of the percent remaining of CAPA or CAPE was 
calculated and plotted against time. Linear regression was performed on these data points 
and the first order rate constant of decomposition was calculated from the slope of the 
linear regression line. Stability profiles of CAPA and CAPE are shown in Figure 4.2 and 
tabulated in Tables 4.5 and 4.6. An energy of activation (Ea) was calculated for both 
CAPA and CAPE by applying the Arrhenius equation. The correlation coefficients of the 
linear regression line from the Arrhenius plot were found to be R
2
 = 0.999 for CAPA and 
R
2
 = 0.998 for CAPE as shown in Figure 4.3. The activation energies for CAPA and 
CAPE were found to be 22.1 kcal/mol, and 14.1 kcal/mol, respectively. The half lives of 
CAPA and CAPE were found to be 10 hours and 0.13 hours at 37 °C, and 41.5 and 0.35 
hours at 25 °C, respectively. The data is reported in Table 4.7. Plasma extracts of 100 
µg/mL CAPA were recovered at 97.6% (3.5 %RSD) following three freeze thaw cycles 
when compared to samples analyzed prior to freezing. Long term stability samples were 
recovered at 97.4% (3.0 %RSD). 
The stability of CAPE in rat plasma has been reported previously and it was 
shown that the decomposition of CAPE was similarly rapid [143]. Slight differences in 
decomposition rate constants may be attributed to variability in enzyme activity between 
different batches of plasma. Plasma stability is an important factor in drug discovery and 
development, as compounds which are highly labile in serum tend to have poor in vivo 






Figure 4.2 - (A) Stability profiles of CAPE (n=3 for all temps):  60 °C (      , R
2
 = 0.987), 
37 °C (      , R
2
 = 0.997), and 25 °C (      , R
2
 = 0.975), (B) Stability profiles 
of CAPA (n=3 for all temps):  37 °C (      , R
2
 = 0.969), 25 °C (      , R
2
 = 
0.974), and 4 °C (      , R
2
 = 0.999). Standard deviations are reported in 

















































Stability  % remaining of CAPA 
  0 h 0.25h 0.5 h 1 h 2 h 3 h   
  100.0 90.6 73.5 54.4 23.7 7.7   
60°C  100.0 86.3 71.8 53.5 22.8 7.6   
  100.0 91.0 75.3 55.7 24.1 7.9   
AVG   89.3 73.5 54.5 23.5 7.7   
SD   2.6 1.8 1.1 0.6 0.1   
%RSD   2.9 2.4 2.1 2.7 1.9   
          
          
  0 h 1 h 2 h 4 h 6 h 24 h 27 h 29.5h 
  100.0 94.8 92.0 85.5 70.8 18.5 15.3 14.9 
37°C  100.0 97.8 86.9 83.8 70.3 18.6 15.4 14.3 
  100.0 97.7 88.1 81.6 71.0 18.7 15.1 14.7 
AVG   96.8 89.0 83.6 70.7 18.6 15.3 14.6 
SD   1.7 2.6 2.0 0.4 0.1 0.1 0.3 
%RSD   1.8 3.0 2.3 0.5 0.6 0.8 2.4 
          
          
  0 h 7 h 24 h 48 h 72 h    
  100.0 91.2 77.4 49.5 30.0    
25°C  100.0 93.0 79.9 51.7 30.2    
  100.0 91.9 81.0 50.8 29.1    
AVG   92.0 79.4 50.7 29.8    
SD   0.9 1.9 1.1 0.6    
%RSD   1.0 2.4 2.2 1.9    
          









Stability  % remaining of CAPE 
  0h 0.17h 0.33h 0.50h 0.67h 
  100.0 37.7 22.0 9.1 2.0 
37°C  100.0 39.0 21.8 9.3 2.0 
  100.0 41.6 23.5 10.3 2.2 
AVG   39.4 22.4 9.6 2.1 
SD   2.0 0.9 0.7 0.1 
%RSD   5.0 4.2 7.0 5.5 
       
       
  0h 0.5h 1h 1.5h 2h 
  100.0 51.6 19.7 8.5 1.8 
25°C  100.0 54.1 19.0 8.3 1.6 
  100.0 53.9 19.1 8.3 1.6 
AVG   53.2 19.3 8.4 1.7 
SD   1.4 0.4 0.1 0.1 
%RSD   2.6 1.9 1.1 7.6 
       
       
  0h 1h 2h 3h 6h 
  100.0 68.9 51.0 35.4 12.1 
4°C  100.0 68.1 50.8 33.3 11.6 
  100.0 67.7 49.1 35.5 11.5 
AVG   68.2 50.3 34.7 11.7 
SD   0.6 1.0 1.2 0.3 
%RSD   0.9 2.1 3.5 2.4 
       




Figure 4.3 - Arrhenius plots for CAPA (    , R
2
 = 0.999) and CAPE (     , R
2








































   
25 0.016 41.5  
37 0.069 10.0 22.1 
60 0.85 0.82  
 
CAPE 
   
4 0.36 1.95  
25 2.01 0.35 14.1 
37 5.51 0.13  
    
 















4.4 – DISCUSSION AND CONCLUSIONS 
 
A simple HPLC method with UV detection was validated and used for the 
determination of plasma stability for CAPA and CAPE. The amide derivatization of 
CAPE significantly improves the stability of the compound in rat plasma as evidenced by 

























Chapter 5 – Pharmacokinetics of CAPA 
 
5.1 – INTRODUCTION 
 
The previously discussed stability studies show that CAPE is rapidly hydrolyzed 
in male Sprague-Dawley rat plasma, and that CAPA’s half-life was significantly longer 
than CAPE’s (Chapter 4). Similarly rapid hydrolysis of CAPE was seen in a previous 
investigation which compared the stability of CAPE to a fluorinated CAPE derivative. It 
has also been found that this rapid hydrolysis can be prevented by the addition of 0.4% 
NaF and 0.1M acetate buffer [143]. The purpose of the following study was to determine 
whether the improvement upon the in vitro stability of CAPE translates to increased 
elimination half-life of the compound in vivo. A validated liquid chromatography mass 
spectrometry (LCMS) method was developed and used for the quantitative determination 
of CAPA and CAPE following extraction from rat serum samples. The pharmacokinetic 
parameters of CAPA were investigated at 5, 10, and 20 mg/kg doses with CAPE 











5.2 – MATERIALS AND METHODS 
 




CAPE (> 98%) and trans-resveratrol (> 98%) were obtained from Cayman 
Chemical (Ann Arbor, MI). CAPA was previously synthesized in our laboratories [181]. 
Sodium fluoride, sodium acetate, propylene glycol, ethanol and acetic acid were 
purchased from Sigma-Aldrich (St Louis, MO). Lithium heparin blood collection vials 
were obtained from BD (Franklin Lakes, NJ). Water used in the procedures was passed 
through a Millipore (Billerica, MA, USA) Milli-Q water purification system (18.2MΩ). 




Jugular vein catheterized male Sprague-Dawley rats (290-350 g) were purchased from 
Charles River. The rats were housed in a temperature controlled room with 12 hour 
light/dark cycles following arrival to the facility. The rats were allowed to acclimate for a 
minimum of 3 days prior to the start of the experiments and were provided with food and 
water ad libitum. All animal experimental procedures were approved by the University of 
Texas Health Science Center at San Antonio and met the Institutional Animal Care and 




An Agilent 1100/1200 series LCMS was used for the quantitative determination 
of CAPA and CAPE. The system was comprised of a 1200 series degasser, binary pump, 
high performance autosampler and column thermostat. This was coupled to an 1100 
series single quadrupole mass spectrometer with a multi-mode ESI/APCI ionization 
chamber. A Phenomenex (Torrance, CA) Synergi MAX-RP (150 mm x 2.0 mm i.d., 4.0 
µm, 80 Å) column controlled at 35 °C was used for the separation of the compounds. The 
mobile phase consisted of water (solvent A) and acetonitrile (solvent B) being run at 500 
µl/min. A gradient elution of 25%B to 98%B over 1 minute, with 98%B held for 4 
minutes, was used to separate CAPA and CAPE from other plasma components and from 
the internal standard (resveratrol).  
Electrospray ionization (ESI) was used in negative ion mode, with capillary 
voltage at 2000 V, fragmentor voltage at 70 V, nebulizer pressure at 60 psig, drying gas 
flow at 10 L/min, drying gas temperature at 300 °C and nebulizer temperature at 150 °C. 
Transitions of parent ion to major product ion were 282/135 m/z for CAPA, 283/133 m/z 
for CAPE and 227/143 m/z for resveratrol. Compound fragmentation was performed with 








5.2.2 – Pharmacokinetic Study 
 
Solutions of CAPA and CAPE were made up in 45% propylene glycol, 40% 
sterile saline and 15% ethanol. Rats were divided into 4 groups of 5 rats each: 20 mg/kg 
CAPA, 10 mg/kg CAPA, 5 mg/kg CAPA and 20 mg/kg CAPE. The compounds were 
administered intravenously (~0.5 ml) over a 10 second period via jugular vein catheter 
with injection volumes normalized to body weight. The catheter was flushed with 0.1 ml 
of heparinized saline following injection to ensure complete delivery of the compounds 
as well as to prevent clotting of the catheter. Blood samples (0.4 ml) were drawn pre-
injection as well as at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 8 h for CAPA and at 5 min, 15 
min, 30 min, 1 h, 1.5 h, 2 h and 3 h for CAPE. Sterile saline (0.4 ml) was injected into the 
catheter following withdrawal of the blood with 0.1 ml of heparinized saline 
subsequently flushed into the catheter. Blood samples were collected in 0.5 ml lithium 
heparin blood collection vials and immediately centrifuged at 10,000 RCF for 5 minutes. 
The plasma layer (~200 µl) was removed and transferred to microtubes containing 50 µl 
of 2% sodium fluoride in 0.5 M acetate buffer (pH= 5). Once mixed, this provided a final 
solution of 0.4% NaF in 0.1M acetate buffer (pH = 5). This was done to prevent 
hydrolysis of CAPE during handling and storage. The plasma samples were frozen at -80 







5.2.3 – LCMS assay validation 
 
Extraction of CAPA and CAPE from plasma followed the procedure described in 
chapter 4. Briefly, 20 µl of the internal standard resveratrol (40 µg/ml) was introduced to 
the plasma samples immediately prior to extraction. The plasma samples were treated 
with 600 µl of ethyl acetate, vortexed for 5 minutes and then centrifuged at 13,000 RCF 
for 5 minutes. The organic layer was removed and the process repeated. The ethyl acetate 
layers were then pooled and concentrated via the Thermo Scientific SpeedVac (Waltham, 
MA) centrifugal vacuum. The samples were diluted 2X by reconstitution with 400 µl of 
MeOH, then vortexed and analyzed on the LCMS.   
The LCMS method was qualified by generation of a calibration curve and 
establishment of selectivity, sensitivity, and both intra-day and inter-day precision and 
accuracy. Extraction recovery and stability of the compounds in plasma have been 
previously described. Analyte response was expressed as CAPA/resveratrol signal area 
ratio and CAPE/resveratrol signal area ratio.  
Blank rat plasma was spiked with CAPA and CAPE at concentrations of 2, 20, 
100, 500, 1000, and 2000 ng/ml using 5 replicates per concentration and quantified with 
the LCMS using the previously described conditions to construct a calibration curve. 
Selectivity was established by utilizing LCMS conditions such that analyte quantification 
was free from interferences. Sensitivity was established by determining the limit of 
detection (LOD) and the lower limit of quantification (LLOQ). The LOD was defined as 
the minimum concentration of analyte needed to produce a signal/noise ratio of 3:1, and 
the LLOQ was defined as the lowest concentration on the calibration curve that must 
produce a signal/noise ratio of at least 5:1. Precision was determined by spiking blank rat 
plasma with CAPA and CAPE at low, medium and high concentrations (20, 500, 2000 
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ng/ml) at five replicates per concentration and calculating the percent relative standard 
deviation (%RSD) of the analyte responses. Both intra-day and inter-day (3 consecutive 
days) precision measurements were performed. Precision was considered acceptable if 
%RSD did not exceed 15%. Accuracy was evaluated as percent deviation from the mean 
of the true value. The true value was defined as the analyte response obtained from the 
calibration curve standards. Accuracy was assessed at low, medium and high 
concentrations (20, 500, 2000 ng/ml) at 5 replicates per concentration and was considered 
acceptable if no value deviated more than 15% from the true value.  
Quality control (QC) samples of known concentration were randomly inserted 
between rat plasma samples during LCMS analysis at a ratio of 1 QC sample per 8 
plasma samples. LCMS runs were considered acceptable if the QC samples did not 














5.2.4 – Pharmacokinetic analysis 
 
Plasma concentrations of CAPA and CAPE were modeled as a function of time 
using WinNonLin version 2.1 by Pharsight (Sunnyvale, CA). Pharmacokinetic 
parameters were obtained by non-compartmental analysis as well as through a non-linear 
fit to the bi-exponential equation. The first order elimination rate constant (λZ) was 
calculated during NCA using a log-linear regression of data points visually selected in the 
terminal phase of the plasma concentration-time plot. The calculation for half-life is 
shown in Equation 5.1. The area under the curve (AUC) was calculated using the linear 
trapezoidal rule, with AUC∞ defined as the area under the plasma concentration-time 
curve from time zero (t0) to time infinity (∞) (Equation 5.2). The calculation for the area 
under the plasma concentration first moment time curve from t0 to ∞ (AUMC∞) is shown 
in Equation 5.3. The calculations for volume of distribution (Varea), total body clearance 







                                                     (5.1) 
 
AUC∞ =     Ci + Ci−1 (ti − ti−1)(
1
2
)ni=1 +  
Clast
𝜆𝑍
                                   (5.2) 
 











i=1            (5.3) 
 
𝑉𝑎𝑟𝑒𝑎 =  
𝐷𝑜𝑠𝑒
𝐴𝑈𝐶∞ ∗𝜆𝑍




𝐶𝑙𝑇 =  
𝐷𝑜𝑠𝑒
𝐴𝑈𝐶∞
                          (5.5) 
 
𝑀𝑅𝑇 =  
𝐴𝑈𝑀𝐶∞
𝐴𝑈𝐶∞
                                                 (5.6) 
 
The plasma concentration-time data was also analyzed as a two-compartment 
model (Scheme 5.1) after observing a bi-exponential decline. The curve was fitted to 
Equation 5.7. The variables A, B, α and β were obtained from the intercepts and slopes of 
the distribution and elimination phases of the plasma concentration time curve, obtained 
by method of residuals. k10, k12, and k21 were defined as the first order elimination rate 
constant from the central compartment, first order transfer rate constant from the central 
compartment to the periphery and first order transfer rate constant from the periphery to 
the central compartment, respectively. The calculations for the following variables are 
shown below: Volume of the central compartment (Vc), volume of distribution at steady 
state (Vss), volume of distribution (Varea), area under the plasma concentration vs time 
curve from t0 to ∞ (AUC∞), area under the first moment time curve from t0 to ∞ 














𝐶𝑝 = 𝐴𝑒−𝛼𝑡 +  𝐵𝑒−𝛽𝑡                                          (5.7) 
 
𝑉𝑐 =  
𝐷𝑜𝑠𝑒
(𝐴+𝐵)
                                                     (5.8) 
 
𝑉𝑠𝑠 = 𝑀𝑅𝑇 ∗ 𝐶𝑙𝑇                                                (5.9) 
 
𝑉𝛽 =  
𝐷𝑜𝑠𝑒
𝐴𝑈𝐶∞ ∗𝛽
                                                 (5.10) 
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                                           (5.12) 
 
𝐶𝑙𝑇 =  
𝐷𝑜𝑠𝑒
𝐴𝑈𝐶∞
                                                 (5.13) 
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𝑀𝑅𝑇 =  
𝐴𝑈𝑀𝐶∞
𝐴𝑈𝐶∞
                                              (5.14) 
 
        𝛼 +  𝛽 = 𝑘10 + 𝑘12 + 𝑘12                                     (5.15) 
 
𝑘10 =  
𝛼∗ 𝛽
𝑘21
                                                  (5.16) 
 
𝑘21 =  
𝐴∗𝛽+𝐵∗𝛼
𝐴+𝐵
                                              (5.17) 
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The pharmacokinetic parameters were compared across dose groups using 










5.3 – RESULTS 
 
5.3.1 – LCMS assay validation 
 
LCMS chromatograms for CAPA (500 ng/ml), CAPE (500 ng/ml) and resveratrol 
(2000 ng/ml) are shown in Figure 5.1. The full scan mass spectra from 50-350 m/z of the 
CAPA, CAPE and resveratrol parent ions are shown in Figure 5.2. The full scan mass 
spectra from 50-350 m/z of the CAPA, CAPE and resveratrol product ions are shown in 
Figure 5.3. A non-linear analyte response to concentration relationship was observed for 
both CAPA and CAPE. The calibration curves in the range of 2-2000 ng/ml are shown in 
Figures 5.4 and 5.5 and were fit to the following quadratic equations describing the 
relationship between concentration (𝑥) and analyte response (𝑦):  
 
For CAPA: 𝑦 =  −3.73 ∗ 10−7 𝑥2 +   2.26 ∗ 10−3 𝑥 + 0.0149 (R2 = 0.999) 
For CAPE: 𝑦 =  −1.37 ∗ 10−6 𝑥2 +   6.65 ∗ 10−3 𝑥 + 0.141 (R2 = 0.999)  
 
The LOD was found to be 1 ng/ml and the LLOQ was found to be 2 ng/ml for 
both CAPA and CAPE. Intra-day and inter-day precision values for both CAPA and 
CAPE did not exceed 15 %RSD at any concentration and are shown in Tables 5.1 and 
5.2. Accuracy values did not exceed 15% deviation from the true value for both 
compounds at any tested concentrations. Precision and accuracy determinations are listed 
in Table 5.3. None of the quality control samples exceeded 15% deviation from the true 












Figure 5.2 – Full scan mass spectra of parent ion from 50-350 m/z, 70V fragmentor: A)       





Figure 5.3 – Full scan mass spectra from 50-350 m/z of product ions, 280V fragmentor. 




Figure 5.4 – CAPA calibration curve. Analyte response (CAPA / resveratrol signal ratio) 
is plotted against concentration (2-2000 ng/ml). Data points are fitted to the 
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Figure 5.5 – CAPE calibration curve. Analyte response (CAPE / resveratrol signal ratio) 
is plotted against concentration (2-2000 ng/ml). The data points are fitted to 








































































  0.0626 1.031 2.917 
  0.0571 1.034 2.995 
Day 1 0.0601 1.083 2.984 
  0.0637 1.045 3.184 





nu 1.050 2.921 
  0.0562 1.091 2.952 
Day 2  0.0483 1.070 2.807 
  0.0516 1.079  nu 





0.0561 1.093 3.063 
  0.0452 1.053 3.049 
Day 3  0.0458 1.100 3.057 
  0.0505 1.076 3.187 




AVG 0.0539 1.063 2.97 
SD 0.0058 0.023 0.23 
%RSD 10.74 2.14 7.69 
Table 5.1 – Inter-day precision values for CAPA. Analyte response (CAPA/resveratrol 



















  0.2428 3.402 8.153 
  0.2424 3.075 7.859 
Day 1 0.2134 3.299 7.640 
  0.2242 3.175 8.225 
  0.2459 3.089 7.935 
  
     0.2197 3.434 7.794 
  0.2118 3.096 7.572 
Day 2  0.2164 3.007 7.913 
  0.2225 3.128 7.482 
  0.2154 3.077 7.962 
  
     0.2830 3.159 8.125 
  0.2661 3.033 7.630 
Day 3  0.2401 3.101 8.022 
  0.2450 3.216 7.816 
  0.2601 3.209 7.909 
  
   avg 0.2366 3.167 7.869 
sd 0.0215 0.127 0.219 
%RSD 9.08 4.01 2.78 
Table 5.2 – Inter-day precision values for CAPE. Analyte response (CAPE/resveratrol 











(ng / ml) 
Observed 
Concentration 









CAPA     
20 17.02 ± 1.51 6.17 – 8.86 10.74 14.9 
500 510.4 ± 10.1 1.96 – 2.02 2.13 2.08 
2000 1991 ± 61 1.98 – 4.20 3.63 0.47 
     
CAPE     
20 20.37 ± 0.89 1.89 – 6.64 9.08 1.83 
500 490.3 ± 19.3 2.45 – 5.26 4.01 1.94 
2000 1965 ± 51 2.42 – 2.95 2.78 1.76 
 















5.3.2 – Pharmacokinetics  
 
The averaged plasma concentration (Cp) vs time profiles for the 3 doses of CAPA 
following intravenous bolus administration to male Sprague-Dawley rats are shown as a 
semi-logarithmic plot in Figure 5.6 and in Figure 5.7 for the 20 mg/kg CAPE dose group. 
The plasma concentration data for the individual rats in each CAPA dose group are 
presented in Tables 5.4-5.6 and plotted in Figures 5.7-5.9. Cp vs time data for individual 













Figure 5.6 – Semi logarithmic representation of the averaged plasma concentration vs 
time profiles for CAPA administered at 20, 10 and 5 mg/kg doses via 


































Figure 5.7 – Semi logarithmic representation of the averaged plasma concentration vs 
time profile for CAPE administered at 20 mg/kg via intravenous bolus to 





























Time (min) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
5 1299 1726 1596 1194 1359 1435 220 
30 903.5 672.8 505.1 182.4 339.3 520.6 281.6 
60 414.0 440.3 305.4 147.9 284.8 318.5 116.6 
120 384.1 425.3 238.4 111.2 214.9 274.8 128.7 
240 293.3 234.9 169.2 103.4 124.6 185.1 78.7 
360 103.0 138.8 118.5 76.7 71.1 101.6 28.4 
480 70.48 86.78 114.18 65.20 70.12 81.35 20.08 
        
Wt (g) 290 315 340 321 330 319 19 
Dose (mg) 5.80 6.30 6.80 6.42 6.60 6.38 0.38 
        
Table 5.4 – Observed individual CAPA plasma concentrations (ng/ml) following 

















Figure 5.8 – Semi logarithmic representation of the individual plasma concentration vs 
time profiles for CAPA administered at 20 mg/kg via intravenous bolus to 
































Time (min) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
5 nu 565.9 773.6 296.5 393.3 507.3 209.6 
30 nu 163.7 81.17 89.11 81.46 103.9 40.06 
60 nu 89.06 42.38 51.06 38.93 55.36 23.04 
120 nu 86.06 27.99 48.08 22.38 46.13 28.82 
240 nu 77.47 20.15 39.57 10.44 36.91 29.63 
360 nu 52.39 13.69 35.18 6.95 27.05 20.74 
480 nu 49.31 11.72 27.01 4.94 23.25 19.68 
        
Wt (g) 341 325 338 302 303 317 18 
Dose (mg) 3.41 3.25 3.38 3.02 3.03 3.17 0.18 
        
Table 5.5 - Observed individual CAPA plasma concentrations (ng/ml) following 
intravenous bolus administration of 10 mg/kg CAPA to male Sprague Dawley 

















Figure 5.9 - Semi logarithmic representation of the individual plasma concentration vs 
time profiles for CAPA administered at 10 mg/kg via intravenous bolus to 































Time (min) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
5 408.1 197.6 447.8 174.2 nu 306.9 128.8 
30 69.95 33.41 37.89 58.40 nu 49.92 19.22 
60 23.19 12.84 25.72 12.26 nu 18.50 14.35 
120 12.15 9.83 7.60 7.87 nu 9.36 6.16 
240 11.13 7.17 5.57 4.81 nu 7.17 2.92 
360 7.64 5.70 4.17 BLOQ nu 5.84 1.74 
480 5.09 4.04 2.91 BLOQ nu 4.01 1.09 
        
Wt (g) 318 324 347 344 296 326 21 
Dose (mg) 1.59 1.62 1.74 1.72 1.48 1.63 0.10 
        
Table 5.6 - Observed individual CAPA plasma concentrations (ng/ml) following 
intravenous bolus administration of 5 mg/kg CAPA to male Sprague Dawley 
















Figure 5.10 - Semi logarithmic representation of the individual plasma concentration vs 
time profiles for CAPA administered at 5 mg/kg via intravenous bolus to 































Time (min) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
5 1848.2 741.8 851.0 1890.1 941.0 1254.4 565.8 
15 672.2 222.7 552.4 366.0 387.7 440.2 174.6 
30 321.1 126.8 280.2 280.7 387.2 279.2 95.7 
60 187.7 103.7 179.3 267.5 185.2 184.5 58.0 
90 186.7 91.3 166.8 188.4 159.8 158.8 39.8 
120 162.9 87.6 141.5 171.1 156.8 144.0 33.3 
180 91.27 44.23 71.53 115.75 136.69 91.89 36.27 
        
Wt (g) 322 314 314 310 321 316 5 
Dose (mg) 6.44 6.28 6.28 6.20 6.42 6.32 0.10 
        
Table 5.7 - Observed individual CAPE plasma concentrations (ng/ml) following 


















Figure 5.11 - Semi logarithmic representation of the individual plasma concentration vs 
time profiles for CAPE administered at 20 mg/kg via intravenous bolus to 































Non compartmental analysis 
 
Non compartmental analysis (NCA) was performed on the plasma concentration 
time data for the CAPA and CAPE dose groups. The results of the NCA for the CAPA 
dose groups are summarized in Tables 5.8-5.10 and in Table 5.11 for the CAPE dose 
group. NCA was performed for individual plasma concentration time profiles as well as 
for the mean plasma concentration time profiles for each dose. The parameters obtained 
from NCA on the mean plasma concentration time curves are shown in Tables 5.12-5.13 
and are seen to be in good agreement with the parameters calculated from the individual 
profiles. One way ANOVA was performed on select parameters obtained from the 
individual profiles from the 3 CAPA dose groups, shown in Table 5.14.  
Non-linear pharmacokinetics were observed for CAPA, as clearance and volume 
of distribution decreased significantly (P < 0.05) with increasing dose. The AUC of 
CAPA also increased non-proportionally with increasing dose, as can be seen in Figure 
5.12. There was no significant difference found in the first order elimination rate constant 
or the half-life of CAPA between the 3 doses. There was a significant difference found in 
the half-life calculated from the NCA between CAPA and CAPE at 20 mg/kg (255.1 









        
Parameters Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
Weight (g) 290 315 340 321 330 319 19 
Dose (mg) 5.8 6.3 6.8 6.42 6.6 6.38 0.38 
        
NCA        
λz (min
-1
) 0.0046 0.0041 0.0024 0.0018 0.0024 0.0031 0.0012 
t1/2 (min) 151.6 169.5 285.4 379.4 289.5 255.1 94.3 
ClT (ml/min) 34.47 35.20 40.86 61.05 53.51 45.02 11.77 
Varea (ml) 7541 8608 16820 33420 22350 17750 10670 
AUC∞ (µg*min/ml) 168.2 178.9 166.4 105.2 123.3 148.4 32.2 
AUMC∞ (mg*min
2
/ml) 31.81 37.11 59.14 46.67 38.44 42.63 10.65 
MRT (min) 189.1 207.3 355.3 443.8 311.7 301.5 105.8 
        
Table 5.8 – Pharmacokinetic parameters obtained from non-compartmental analysis 
















        
Parameters Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
Weight (g) 341 325 338 302 303 317 18 
Dose (mg) 3.41 3.25 3.38 3.02 3.03 3.17 0.18 
        
NCA        
λz (min
-1
) nu 0.0019 0.0025 0.0022 0.0031 0.0024 0.0005 
t1/2 (min) nu 368.2 277.4 314.9 222.5 295.8 61.4 
ClT (ml/min) nu 45.6 109 80.9 175 102.6 54.8 
Varea (ml) nu 24220 43980 36760 56470 40360 13490 
AUC∞ (µg*min/ml) nu 71.29 30.75 37.33 17.22 39.15 23.01 
AUMC∞ (mg*min
2
/ml) nu 33.75 6.18 16.50 2.45 14.72 14.01 
MRT (min) nu 473.4 200.9 442.0 142.0 314.6 167.5 
        
Table 5.9 – Pharmacokinetic parameters obtained from non-compartmental analysis 
















        
Parameters Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
Weight (g) 318 324 347 344 296 325 20.8 
Dose (mg) 1.59 1.62 1.74 1.72 1.48 1.63 0.10 
        
NCA        
λz (min
-1
) 0.0026 0.0024 0.0027 0.0041 nu 0.0030 0.0008 
t1/2 (min) 265.2 284.9 253.7 168.8 nu 243.2 51.2 
ClT (ml/min) 98.5 170.5 125.3 229.9 nu 156.1 57.5 
Varea (ml) 37690 70120 45870 55990 nu 52420 13970 
AUC∞ (µg*min/ml) 16.14 9.50 13.84 7.48 nu 11.74 3.96 
AUMC∞ (mg*min
2
/ml) 2.758 2.234 1.543 0.815 nu 1.837 0.844 
MRT (min) 170.9 235.2 111.5 108.9 nu 156.6 59.7 
        
 
Table 5.10 – Pharmacokinetic parameters obtained from non-compartmental analysis 















        
Parameters Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
Weight (g) 322 314 314 310 321 316 5.1 
Dose (mg) 6.44 6.28 6.28 6.2 6.42 6.32 0.10 
        
NCA        
λz (min
-1
) 0.0082 0.0085 0.0097 0.0066 0.0058 0.0078 0.0016 
t1/2 (min) 84.1 81.3 71.6 105.0 119.4 92.3 19.5 
ClT (ml/min) 92.3 201.8 129.0 79.6 97.5 120.0 49.2 
Varea (ml) 11230 23850 13360 12010 15950 15280 5110 
AUC∞ (µg*min/ml) 69.52 30.89 48.51 78.18 69.34 59.29 19.27 
AUMC∞ (mg*min
2
/ml) 5.96 2.84 4.34 8.68 11.02 6.57 3.30 
MRT (min) 85.8 92.0 89.5 111.0 159.0 107.4 30.4 
        
Table 5.11 – Pharmacokinetic parameters obtained from non-compartmental analysis 
















       













NCA       
λz (min
-1
) 0.0031 0.0035 0.0024 0.0019 0.0030 0.0033 
t1/2 (min) 255.1 200.4 295.8 359 243.2 207.7 
ClT (ml/min) 45.02 44.90 102.6 79.3 156.1 124.0 
Varea (ml) 17750 12980 40360 41150 52420 37330 
AUC∞ (µg*min/ml) 148.4 142.1 39.15 39.98 11.74 13.08 
AUMC∞ (mg*min
2
/ml) 42.63 34.51 14.72 15.73 1.837 1.818 
MRT (min) 301.5 242.9 314.6 393.3 156.6 139 
       
Table 5.12 – Pharmacokinetic parameters obtained from non-compartmental analysis 
(NCA) of the CAPA dose groups. Comparison between the average of the 
individually obtained pharmacokinetic parameters (mean ind.) and the 





















NCA   
λz (min
-1
) 0.0078 0.0068 
t1/2 (min) 92.3 101.4 
ClT (ml/min) 120.0 106.6 
Varea (ml) 15280 15560 
AUC∞ (µg*min/ml) 59.29 59.48 
AUMC∞ (mg*min
2
/ml) 6.57 6.75 
MRT (min) 107.4 113.4 
   
 
Table 5.13 – Pharmacokinetic parameters obtained from non-compartmental analysis 
(NCA) of the 20 mg/kg CAPE dose group. Comparison between the average 
of the individually obtained pharmacokinetic parameters (mean ind.) and the 

















(AVG ± SD) 
10 mg/kg 
(AVG ± SD) 
5 mg/kg 
(AVG ± SD) 
ANOVA 
P Value 
     
NCA     
t1/2 (min) 255.1 ± 94.3 295.75 ± 61.43 243.1 ± 51.2 > 0.05 
ClT (ml/min) 45.02 ± 11.77 102.6 ± 54.8 156.1 ± 57.5 < 0.05 
Varea (ml) 17750 ± 10670 40360 ± 13490 52420 ± 13980 < 0.05 
AUC∞ (µg*min/ml) 148.42 ± 32.21 39.15 ± 23.01 11.74 ± 3.96 < 0.05 
     
Table 5.14 – Averaged pharmacokinetic parameters obtained from non-compartmental 
analysis (NCA) on the individual plasma concentration time profiles for the 


















Figure 5.12 – Relationship between administered dose of CAPA and resulting AUC∞ 





































Bi-exponential fit  
 
The plasma concentration time data was analyzed as a two compartment model 
and fit to Equation 5.7. The fit of the average plasma concentration time profiles of the 
CAPA dose groups to the bi-exponential equation can be seen in Figures 5.13-5.15. Fit of 
the CAPE plasma concentration time profile to the bi-exponential equation can be seen in 
Figure 5.16. The pharmacokinetic parameters calculated from the compartmental analysis 
of the CAPA plasma concentration time profiles are summarized in Tables 5.15-5.17. 
Parameters obtained for CAPE are summarized in Table 5.18. Bi-exponential fit to 
Equation 5.7 was performed for individual plasma concentration time profiles as well as 
for the mean plasma concentration time profiles for each dose. The parameters obtained 
from the bi-exponential fit on the mean plasma concentration time curves of both CAPA 
and CAPE are shown in Tables 5.19-5.20 and are seen to be in good agreement with the 
parameters calculated from the individual profiles. One way ANOVA was performed on 
select parameters obtained from the individual profiles from the 3 CAPA dose groups; 
shown in Table 5.21.   
Non-linear pharmacokinetics were observed for CAPA as clearance and volume 
of distribution decreased significantly (P < 0.05) with increasing dose. These trends were 
similar to what was observed in the same parameters obtained from NCA. The AUC of 
CAPA also increased non-proportionally with increasing dose, as can be seen in Figure 
5.17, again similar to what was observed in the NCA. There was good agreement 
between the parameters obtained via NCA and parameters obtained via bi-exponential fit. 
A comparison of select pharmacokinetic parameters calculated via both methods is 
shown in Table 5.22 for the CAPA dose groups and in Table 5.23 for the 20 mg/kg 
CAPE dose group. It is seen again that the half-life of CAPA at 20 mg/kg is longer and 
 137 
significantly different from the half-life of CAPE at 20 mg/kg (257.5 minutes for 20 






















         
Figure 5.13 – Bi-exponential fit of the mean plasma concentration time profile of the 20 
mg/kg CAPA dose group. Observed concentrations are shown along with 
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Figure 5.14 – Bi-exponential fit of the mean plasma concentration time profile of the 10 
mg/kg CAPA dose group. Observed concentrations are shown along with 
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Figure 5.15 – Bi-exponential fit of the mean plasma concentration time profile of the 5 
mg/kg CAPA dose group. Observed concentrations are shown along with 
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Figure 5.16 – Bi-exponential fit of the mean plasma concentration time profile of the 20 
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Parameters Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
Weight (g) 290 315 340 321 330 319 19 
Dose (mg) 5.8 6.3 6.8 6.42 6.6 6.38 0.38 
        
Bi-exponential fit        
A (ng/ml) 918.2 1751 1837 2040 1824 1674 435 
B (ng/ml) 563.1 589.4 320.6 155.3 289.0 383.5 186.8 
α (min
-1
) 0.036 0.084 0.072 0.135 0.106 0.087 0.037 
β (min
-1
) 0.0041 0.0038 0.0025 0.0019 0.0024 0.0029 0.0009 
k10 (min
-1
) 0.0090 0.0132 0.0140 0.0220 0.0154 0.0147 0.0047 
k12 (min
-1
) 0.0147 0.0510 0.0480 0.1030 0.0765 0.0586 0.0331 
k21 (min
-1
) 0.0160 0.0240 0.0130 0.0110 0.0166 0.0161 0.0049 
t1/2 α (min) 19.27 8.22 9.56 5.15 6.54 9.75 5.58 
t1/2 β (min) 169.1 183.3 278.4 367.9 288.8 257.5 82.1 
ClT (ml/min) 35.61 35.67 44.12 65.79 47.96 45.83 12.38 
Vc (ml) 3915 2692 3151 2925 3123 3161 459 
Varea (ml) 8686 9388 17650 34620 19980 14900 10500 
Vss (ml) 7479 8372 14910 29570 17540 15570 8910 
AUC∞ (µg*min/ml) 162.9 176.6 154.1 97.6 137.6 145.8 30.4 
AUMC∞ (mg*min
2
/ml) 34.21 41.06 51.65 43.14 50.34 44.08 7.14 
MRT (min) 210.0 234.1 337.0 449.0 365.6 319.1 98.1 
        
Table 5.15 - Pharmacokinetic parameters obtained from the plasma concentration time 










        
Parameters Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
Weight (g) 341 325 338 302 303 317 18 
Dose (mg) 3.41 3.25 3.38 3.02 3.03 3.17 0.18 
        
Bi-exponential fit        
A (ng/ml) nu 689.9 1295 350.0 529.9 716.3 410.3 
B (ng/ml) nu 96.99 43.10 52.99 34.39 56.87 27.81 
α (min
-1
) nu 0.077 0.114 0.076 0.078 0.086 0.019 
β (min
-1
) nu 0.0019 0.0028 0.0021 0.0034 0.0026 0.0007 
k10 (min
-1
) nu 0.0130 0.0501 0.0140 0.0333 0.0276 0.0177 
k12 (min
-1
) nu 0.0546 0.0607 0.0530 0.0397 0.0520 0.0088 
k21 (min
-1
) nu 0.0111 0.0064 0.0118 0.0079 0.0093 0.0026 
t1/2 α (min) nu 9.00 6.06 9.12 8.90 8.27 1.48 
t1/2 β (min) nu 364.8 247.6 330.1 203.9 286.6 73.9 
ClT (ml/min) nu 54.2 126.5 101.2 178.9 115.2 52.0 
Vc (ml) nu 4129 2525 7493 5369 4879 2096 
Varea (ml) nu 28500 45180 48190 52600 43620 10530 
Vss (ml) nu 24350 26500 40960 32340 31040 7420 
AUC∞ (µg*min/ml) nu 60.00 26.72 29.84 16.94 33.38 18.59 
AUMC∞ (mg*min
2
/ml) nu 26.98 5.59 12.07 3.06 11.93 10.73 
MRT (min) nu 449.7 209.5 404.7 180.8 311.2 135.7 
        
 
Table 5.16 - Pharmacokinetic parameters obtained from the plasma concentration time 









        
Parameters Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
Weight (g) 318 324 347 344 296 325 20.8 
Dose (mg) 1.59 1.62 1.74 1.72 1.48 1.63 0.10 
        
Bi-exponential fit        
A (ng/ml) 580.8 284.5 587.7 215.0 nu 417.0 195.2 
B (ng/ml) 20.02 12.99 9.52 4.79 nu 11.83 6.41 
α (min
-1
) 0.081 0.086 0.058 0.047 nu 0.068 0.019 
β (min
-1
) 0.0028 0.0024 0.0024 0.0058 nu 0.0034 0.0016 
k10 (min
-1
) 0.0420 0.0340 0.0420 0.0407 nu 0.0397 0.0038 
k12 (min
-1
) 0.0360 0.0480 0.0150 0.0054 nu 0.0261 0.0194 
k21 (min
-1
) 0.0053 0.0061 0.0033 0.0067 nu 0.0054 0.0015 
t1/2 α (min) 8.60 8.02 11.82 14.75 nu 10.80 3.12 
t1/2 β (min) 249.5 290.4 294.5 119.5 nu 238.5 81.9 
ClT (ml/min) 110 185 123 319 nu 184 95 
Vc (ml) 2646 5445 2905 7825 nu 4705 2433 
Varea (ml) 39390 77250 51370 54920 nu 55730 15810 
Vss (ml) 20520 49200 16570 14140 nu 25110 16280 
AUC∞ (µg*min/ml) 14.42 8.74 14.07 5.40 nu 10.66 4.36 
AUMC∞ (mg*min
2
/ml) 2.642 2.294 1.827 2.397 nu 1.751 1.061 
MRT (min) 186.0 265.4 134.0 44.4 nu 157.4 92.7 
        
 
Table 5.17 - Pharmacokinetic parameters obtained from the plasma concentration time 









        
Parameters Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Mean SD 
        
Weight (g) 322 314 314 310 321 316 5.1 
Dose (mg) 6.44 6.28 6.28 6.2 6.42 6.32 0.10 
        
Bi-exponential fit        
A (ng/ml) 3085 1677 845 3999 1639 2249 1268 
B (ng/ml) 339.1 173.2 304.7 304.3 345.0 294.3 70.7 
α (min
-1
) 0.141 0.214 0.080 0.192 0.201 0.166 0.055 
β (min
-1
) 0.0074 0.0079 0.0081 0.0059 0.0063 0.0071 0.0009 
k10 (min
-1
) 0.0506 0.0622 0.0240 0.0594 0.0312 0.0455 0.0171 
k12 (min
-1
) 0.0775 0.1325 0.0370 0.1190 0.1352 0.1002 0.0422 
k21 (min
-1
) 0.0207 0.0272 0.0270 0.0190 0.0405 0.0269 0.0085 
t1/2 α (min) 4.90 3.24 8.66 3.61 3.45 4.77 2.27 
t1/2 β (min) 93.7 87.7 85.6 117.4 110.0 98.9 14.1 
ClT (ml/min) 95.2 211.0 130.4 85.6 100.7 124.6 51.1 
Vc (ml) 1881 3394 5461 1440 3228 3081 1575 
Varea (ml) 12870 26710 16100 14500 15990 17230 5460 
Vss (ml) 8930 19930 12920 10450 14010 13250 4240 
AUC∞ (µg*min/ml) 67.64 29.76 48.17 72.42 63.73 56.34 17.42 
AUMC∞ (mg*min
2
/ml) 6.346 2.812 4.775 8.843 8.860 6.327 2.622 
MRT (min) 93.8 94.5 99.1 122.1 139.0 109.7 20.1 
        
 
Table 5.18 - Pharmacokinetic parameters obtained from the plasma concentration time 









       













Bi-exponential fit       
A (ng/ml) 1674 1526 716.3 700.9 417.0 443.3 
B (ng/ml) 383.5 384 56.87 58.68 11.83 16.97 
α (min
-1
) 0.087 0.074 0.086 0.089 0.068 0.085 
β (min
-1
) 0.0029 0.0033 0.0026 0.002 0.0034 0.0033 
k10 (min
-1
) 0.0147 0.0140 0.0276 0.0205 0.0397 0.0445 
k12 (min
-1
) 0.0586 0.0455 0.0520 0.0618 0.0261 0.0372 
k21 (min
-1
) 0.0161 0.0170 0.0093 0.0087 0.0054 0.0063 
t1/2 α (min) 9.75 9.42 8.27 7.79 10.80 8.18 
t1/2 β (min) 257.5 211.0 286.6 345.4 238.5 208.4 
ClT (ml/min) 45.83 46.25 115.2 85.4 184 158 
Vc (ml) 3161 3338 4879 4173 4705 3539 
Varea (ml) 14900 14020 43620 40680 55730 47390 
Vss (ml) 15570 12060 31040 33730 25110 24350 
AUC∞ (µg*min/ml) 145.8 137.9 33.38 37.12 10.66 10.33 
AUMC∞ (mg*min
2
/ml) 44.08 35.54 11.93 14.66 1.751 1.596 
MRT (min) 319.1 260.7 311.2 394.9 157.4 154.5 
       
Table 5.19 – Pharmacokinetic parameters obtained from the bi-exponential fit of the 
plasma concentration time profiles of the CAPA dose groups. Comparison 
between the average of the individually obtained pharmacokinetic 
parameters (mean ind.) and the parameters obtained from the averaged 














Bi-exponential fit   
A (ng/ml) 2249 2305 
B (ng/ml) 294.3 310.4 
α (min
-1
) 0.166 0.176 
β (min
-1
) 0.0071 0.0070 
k10 (min
-1
) 0.0455 0.0450 
k12 (min
-1
) 0.1002 0.1100 
k21 (min
-1
) 0.0269 0.0270 
t1/2 α (min) 4.77 3.92 
t1/2 β (min) 98.9 99.0 
ClT (ml/min) 124.6 110.0 
Vc (ml) 3081 2416 
Varea (ml) 17230 15740 
Vss (ml) 13250 12280 
AUC∞ (µg*min/ml) 56.34 57.38 
AUMC∞ (mg*min
2
/ml) 6.327 6.398 
MRT (min) 109.7 111.5 
   
Table 5.20 – Pharmacokinetic parameters obtained from the bi-exponential fit of the 
plasma concentration time profiles of the 20 mg/kg CAPE dose group. 
Comparison between the average of the individually obtained 
pharmacokinetic parameters (mean ind.) and the parameters obtained from 













(AVG ± SD) 
10 mg/kg 
(AVG ± SD) 
5 mg/kg 
(AVG ± SD) 
ANOVA 
P Value 
     
Bi-exponential fit     
t1/2 (min) 257.5 ± 82.1 286.6 ± 73.9 238.5 ± 81.9 > 0.05 
ClT (ml/min) 45.83 ± 12.38 115.2 ± 51.9 184.1 ± 95.4 < 0.05 
  Varea (ml) 14900 ± 10500 43620 ± 10530 55720 ± 15810 < 0.05 
AUC∞ (µg*min/ml) 145.8 ± 30.4 33.38 ± 18.59 10.66 ± 4.36 < 0.05 
MRT (min) 319.1 ± 98.1 311.2 ± 135.7 157.4 ± 92.7 > 0.05 
     
Table 5.21 – Averaged pharmacokinetic parameters obtained from the bi-exponential fit 
of the individual plasma concentration time profiles for the 3 CAPA dose 

















       
Figure 5.17 – Relationship between administered dose of CAPA and resulting AUC∞ 








































       
 20 mg/kg 10 mg/kg 5 mg/kg 
Parameters NCA Fit NCA Fit NCA Fit 
       
t1/2 (min) 255.1 257.5 295.8 286.6 243.2 238.5 
ClT (ml/min) 45.02 45.83 102.6 115.2 156.1 184 
Varea (ml) 17750 14900 40360 43620 52420 55730 
AUC∞ (µg*min/ml) 148.4 145.8 39.15 33.38 11.74 10.66 
MRT (min) 301.5 319.1 314.6 311.2 156.6 157.4 
       
Table 5.22 – Mean pharmacokinetic parameters obtained via non-compartmental analysis 
(NCA) and bi-exponential fit to the two compartment model (Fit) of the 
CAPA plasma concentration time profiles. Elimination half-life (t1/2), total 
clearance (ClT), volume of distribution (Varea), area under the curve from 
















   
 CAPE 20 mg/kg 
Parameters NCA Fit 
   
t1/2 (min) 92.3 98.9 
ClT (ml/min) 120.0 124.6 
Varea (ml) 15280 17230 
AUC∞ (µg*min/ml) 59.29 56.34 
MRT (min) 107.4 109.7 
   
 
Table 5.23 – Mean pharmacokinetic parameters obtained via non compartmental analysis 
(NCA) and bi-exponential fit to the two compartment model (Fit) of the 20 
mg/kg CAPE plasma concentration time profiles. Elimination half-life (t1/2), 
total clearance (ClT), volume of distribution (Varea), area under the curve 















5.4 – DISCUSSION AND CONCLUSIONS 
 
The pharmacokinetic properties of CAPA were investigated at 20 mg/kg, 10 
mg/kg and 5 mg/kg doses. CAPE was investigated at 20 mg/kg. These doses were 
selected based on the previous pharmacokinetic investigation of CAPE. Dose 
proportionality was not observed for the three doses of CAPA. AUC∞ increased more 
than three-fold when dose increased from 5 to 10 mg/kg. A similar three-fold increase in 
AUC∞ was also seen when dose was raised from 10 to 20 mg/kg. Increases in dose were 
met with significant decreases in volume of distribution and in clearance. There were no 
significant differences seen in half-life of CAPA between the three doses. The lower 
volume of distribution at higher doses suggests that more of the compound is available in 
the central compartment and that distribution to the tissues is higher at lower 
concentrations. It is possible that there is significant tissue binding of CAPA in the 
periphery and that this binding is saturable. This would account for the higher volume of 
distribution at lower doses, as a higher proportion of CAPA would be bound in the 
tissues, preventing it from transferring back to the central compartment. If this binding is 
saturated at the higher doses, a higher proportion of CAPA would then be free to transfer 
back to the central compartment after the initial distribution, thus lowering the apparent 
volume of distribution. This possibility would also mean that the first order transfer rate 
constant from the periphery to the central compartment (k21) would increase as dose is 
increased. This increase was observed in our experiments. There was a significant 
difference in k21 between the three tested doses of CAPA (P < 0.05). Further investigation 
is needed to determine whether this tissue binding is responsible for the non-linear 
pharmacokinetics observed. 
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When comparing the 20 mg/kg dose group of CAPA to the 20 mg/kg dose group 
of CAPE, it was seen that the half-life was CAPA was significantly higher than CAPE (P 
< 0.05). This was observed for both the non compartmental analysis and the 2 
compartment analysis. CAPA has been shown to share a few of CAPE’s multitude of 
beneficial properties. It is possible that CAPA’s increased half-life over CAPE may allow 
it to exert its beneficial properties for a longer period of time. It remains to be seen if this 




















Chapter 6 – Conclusions 
 
CAPE has been shown to be an effective cytoprotectant against oxidative stress in 
vitro and against I/R injury in vivo despite having poor in vitro stability and short 
circulation half-life. CAPA is the amide analogue of CAPE and was synthesized to 
improve stability and to increase circulation half-life of the compound. An in vitro 
cytoprotection assay was developed and utilized to investigate whether CAPA retained 
CAPE’s cytoprotective properties. Both compounds were then tested for in vitro stability 
in male Sprague-Dawley rat plasma. Finally a pharmacokinetic study was carried out in 
male Sprague Dawley rats to determine pharmacokinetic parameters for both CAPA and 
CAPE following intravenous bolus administration.  
 
Synthesis and cytoprotective activity of CAPA and CAPA derivatives in HUVEC 
 
CAPA and five catechol ring fluorinated derivatives were synthesized via Wittig 
reaction. CAPA and four of the derivatives showed no cytotoxicity in HUVEC up to 100 
µM. CAPE showed significant toxicity when incubated in HUVEC at 20 µM for the 
same amount of time. This allows the possibility of higher dosing for CAPA over CAPE. 
CAPA was found to be the most cytoprotective derivative against hydrogen peroxide 
induced oxidative stress in HUVEC. Three of the fluorinated derivatives showed 
significant protective activity. Both CAPE and CAPA treated cells were able to 
significantly induce the expression of HO-1 over control with as little as 1 hour of 
exposure time. There were no significant differences found in HO-1 expression between 
cells treated with CAPE and CAPA beyond 2 hours of exposure time. These findings 
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suggest that the cells may not need to be continually exposed to CAPE or CAPA in order 
for a protective effect to be induced. There was no significant difference found in 
cytoprotective activity between CAPA and CAPE against hydrogen peroxide induced 
oxidative stress in HUVEC. These experiments show that amide derivatization does not 
compromise CAPE’s protective activity in HUVEC.   
 
Stability of CAPA in rat plasma 
 
A validated HPLC method with UV detection was developed and used for the 
quantification of CAPA and CAPE following extraction from male Sprague-Dawley rat 
plasma. Stability of CAPA was tested at 25, 37 and 60 °C, and the stability of CAPE was 
tested at 4, 25 and 37 °C. CAPA exhibited a significantly longer half-life than CAPE at 
25 °C (41.5 hours vs 0.35 hours) and 37 °C (10.0 hours vs 0.13 hours). CAPA was also 
shown to have a higher energy of activation than CAPE (22.1 kcal/mol vs 14.1 kcal/mol). 
It is hypothesized that the activity of esterase enzymes is responsible for CAPE’s rapid 
decomposition and that CAPA’s lack of an ester bond allowed for its longer half-life. 
CAPA showed only 8% decomposition after 7 hours at room temperature, suggesting that 
decomposition is negligible during sample handling (on ice) and sample storage (-80 °C). 
This information is useful for future pharmacokinetic studies as post collection 






Pharmacokinetics of CAPA 
 
Pharmacokinetic parameters of CAPA were investigated at 20 mg/kg, 10 mg/kg 
and 5 mg/kg following intravenous bolus administration to male Sprague-Dawley rats. 
The pharmacokinetic parameters of CAPE administered at 20 mg/kg were also 
determined. A LCMS method was developed, qualified and used for the quantification of 
CAPA and CAPE following extraction from rat blood samples. NCA and bi-exponential 
fit were employed to calculate the various pharmacokinetic parameters, with good 
agreement between the two analyses. Non linear pharmacokinetics were observed for 
CAPA as clearance and volume of distribution both decreased significantly with 
increasing dose. Dose proportionality was not observed for CAPA. It is possible that 
saturable tissue binding in the periphery is responsible for the non linear 
pharmacokinetics observed. There was no significant difference in half-life between the 
three doses of CAPA. CAPA at 20 mg/kg showed a significantly longer half-life than 













In conclusion, CAPA was synthesized in attempt to improve the stability of 
CAPE without compromising CAPEs cytoprotective activity. The cytoprotection studies 
show that amide derivatization did not alter CAPE’s protective effects and that CAPA is 
transcriptionally active. The stability studies in rat plasma show that CAPA is indeed 
more stable than CAPE, evidenced by a significantly longer half-life at 25 °C and 37 °C. 
The pharmacokinetic studies show that CAPA remains in the circulation for a 
significantly longer period of time than CAPE. The longer elimination half-life from the 
systemic circulation of CAPA allows for extended exposure times compared to CAPE 
when administered at the same molar dose. Future studies should investigate the effect of 
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